JP2016531119A - Btkの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 - Google Patents
Btkの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 Download PDFInfo
- Publication number
- JP2016531119A JP2016531119A JP2016531850A JP2016531850A JP2016531119A JP 2016531119 A JP2016531119 A JP 2016531119A JP 2016531850 A JP2016531850 A JP 2016531850A JP 2016531850 A JP2016531850 A JP 2016531850A JP 2016531119 A JP2016531119 A JP 2016531119A
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- compound
- pyrimidin
- phenoxyphenoxy
- btk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title abstract description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title abstract description 4
- 239000003112 inhibitor Substances 0.000 title description 17
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 257
- 238000000034 method Methods 0.000 claims description 185
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 81
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 71
- 229910052757 nitrogen Inorganic materials 0.000 claims description 61
- 201000010099 disease Diseases 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 58
- 125000005842 heteroatom Chemical group 0.000 claims description 49
- 229910052760 oxygen Inorganic materials 0.000 claims description 48
- 229910052717 sulfur Inorganic materials 0.000 claims description 48
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 46
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 45
- 239000001301 oxygen Substances 0.000 claims description 45
- 239000011593 sulfur Substances 0.000 claims description 45
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 229920006395 saturated elastomer Polymers 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 30
- 125000001931 aliphatic group Chemical group 0.000 claims description 29
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 125000004429 atom Chemical group 0.000 claims description 19
- 229910005965 SO 2 Inorganic materials 0.000 claims description 18
- 230000001404 mediated effect Effects 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000012472 biological sample Substances 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 230000000069 prophylactic effect Effects 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 7
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 7
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 7
- 206010025135 lupus erythematosus Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 5
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 claims description 5
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000033464 Reiter syndrome Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 208000002574 reactive arthritis Diseases 0.000 claims description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 230000002232 neuromuscular Effects 0.000 claims description 2
- 239000013610 patient sample Substances 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000005801 spondylosis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 208000028780 ocular motility disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 88
- 229940124291 BTK inhibitor Drugs 0.000 abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 97
- -1 bicyclic hydrocarbon Chemical class 0.000 description 94
- 238000004949 mass spectrometry Methods 0.000 description 86
- 238000004128 high performance liquid chromatography Methods 0.000 description 69
- 239000000243 solution Substances 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
- 229910001868 water Inorganic materials 0.000 description 57
- ZSBDGXGICLIJGD-UHFFFAOYSA-N 4-phenoxyphenol Chemical compound C1=CC(O)=CC=C1OC1=CC=CC=C1 ZSBDGXGICLIJGD-UHFFFAOYSA-N 0.000 description 56
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 51
- 238000005160 1H NMR spectroscopy Methods 0.000 description 46
- 239000011541 reaction mixture Substances 0.000 description 44
- 239000000523 sample Substances 0.000 description 42
- ZGJDDWOXVGDTSP-UHFFFAOYSA-N 4-chloro-5h-pyrrolo[3,2-d]pyrimidine Chemical compound ClC1=NC=NC2=C1NC=C2 ZGJDDWOXVGDTSP-UHFFFAOYSA-N 0.000 description 39
- 239000007787 solid Substances 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 32
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
- 102000001253 Protein Kinase Human genes 0.000 description 26
- 108060006633 protein kinase Proteins 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 24
- 125000001424 substituent group Chemical group 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- 210000003719 b-lymphocyte Anatomy 0.000 description 22
- 238000002953 preparative HPLC Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 239000012043 crude product Substances 0.000 description 19
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- 229920001223 polyethylene glycol Polymers 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 16
- 235000017557 sodium bicarbonate Nutrition 0.000 description 16
- 239000013038 irreversible inhibitor Substances 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 150000002431 hydrogen Chemical class 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 239000000975 dye Substances 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 108091008875 B cell receptors Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 230000001363 autoimmune Effects 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 9
- NQQRXZOPZBKCNF-NSCUHMNNSA-N (e)-but-2-enamide Chemical compound C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 208000027866 inflammatory disease Diseases 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 7
- ITGIYLMMAABTHC-ONEGZZNKSA-N (e)-4-(dimethylazaniumyl)but-2-enoate Chemical compound CN(C)C\C=C\C(O)=O ITGIYLMMAABTHC-ONEGZZNKSA-N 0.000 description 7
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 7
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 229910052805 deuterium Inorganic materials 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 125000000160 oxazolidinyl group Chemical group 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 229920003169 water-soluble polymer Polymers 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- ONGHCCOEHRLASK-UHFFFAOYSA-N 3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]pyrrolidine-1-carbonitrile Chemical compound C1N(C#N)CCC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 ONGHCCOEHRLASK-UHFFFAOYSA-N 0.000 description 6
- HHENWMDMGFNJEO-UHFFFAOYSA-N 7-chloro-1h-pyrazolo[4,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1NN=C2 HHENWMDMGFNJEO-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- FCANPIQIVCYRGU-UHFFFAOYSA-N C1NCC1n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C1NCC1n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 FCANPIQIVCYRGU-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- UYEDZZGCKDTSRB-UHFFFAOYSA-N O(c1ccccc1)c1ccc(Oc2ncnc3cc[nH]c23)cc1 Chemical compound O(c1ccccc1)c1ccc(Oc2ncnc3cc[nH]c23)cc1 UYEDZZGCKDTSRB-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 description 6
- 239000002260 anti-inflammatory agent Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 239000007909 solid dosage form Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- TWTWPMCLXGCCRO-QHHAFSJGSA-N (e)-1-[3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]but-2-en-1-one Chemical compound C1N(C(=O)/C=C/C)CC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 TWTWPMCLXGCCRO-QHHAFSJGSA-N 0.000 description 5
- OPJYVZNVLRYURZ-QPJQQBGISA-N (e)-2-[4-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]piperidine-1-carbonyl]hex-2-enenitrile Chemical compound C1CN(C(=O)C(/C#N)=C/CCC)CCC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 OPJYVZNVLRYURZ-QPJQQBGISA-N 0.000 description 5
- MJBSTWLGTSOICH-RMKNXTFCSA-N (e)-4-(dimethylamino)-1-[4-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]piperidin-1-yl]but-2-en-1-one Chemical compound C1CN(C(=O)/C=C/CN(C)C)CCC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 MJBSTWLGTSOICH-RMKNXTFCSA-N 0.000 description 5
- BOOYCYGEOSTTGM-UHFFFAOYSA-N 1-[3-[4-[4-(4-fluorophenoxy)phenoxy]pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1=CC(F)=CC=C1OC(C=C1)=CC=C1OC1=NC=NC2=C1N(C1CN(C1)C(=O)C=C)C=C2 BOOYCYGEOSTTGM-UHFFFAOYSA-N 0.000 description 5
- FSDCJDJTXMUYIE-UHFFFAOYSA-N 1-[3-[6-(4-phenoxyphenyl)pyrrolo[3,2-b]pyridin-1-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC1N1C2=CC(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=CN=C2C=C1 FSDCJDJTXMUYIE-UHFFFAOYSA-N 0.000 description 5
- CTUGGCISGPJTFT-UHFFFAOYSA-N 3-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]pyrrolidine-1-carbonitrile Chemical compound C1N(C#N)CCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 CTUGGCISGPJTFT-UHFFFAOYSA-N 0.000 description 5
- ZCRFIFZXWGHHEP-UHFFFAOYSA-N 4-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]piperidine-1-carbonitrile Chemical compound C1CN(C#N)CCC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 ZCRFIFZXWGHHEP-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- LKPTXKHJMYBMIJ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CC(C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound CC(C)(C)OC(=O)N1CC(C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 LKPTXKHJMYBMIJ-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- DPYMWFYLCPNIDC-UHFFFAOYSA-N n-[4-[5-(1-prop-2-enoylazetidin-3-yl)pyrrolo[3,2-d]pyrimidin-4-yl]oxyphenyl]benzamide Chemical compound C1N(C(=O)C=C)CC1N1C2=C(OC=3C=CC(NC(=O)C=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 DPYMWFYLCPNIDC-UHFFFAOYSA-N 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000004783 oxidative metabolism Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- LOPQWMNOCSRRSR-UHFFFAOYSA-N (3-phenoxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(OC=2C=CC=CC=2)=C1 LOPQWMNOCSRRSR-UHFFFAOYSA-N 0.000 description 4
- ONGHCCOEHRLASK-KRWDZBQOSA-N (3s)-3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]pyrrolidine-1-carbonitrile Chemical compound C1N(C#N)CC[C@@H]1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 ONGHCCOEHRLASK-KRWDZBQOSA-N 0.000 description 4
- VVNOZVPEJKGAJI-RMKNXTFCSA-N (e)-4-(dimethylamino)-1-[3-[3-(4-phenoxyphenyl)pyrrolo[2,3-b]pyrazin-5-yl]azetidin-1-yl]but-2-en-1-one Chemical compound C1N(C(=O)/C=C/CN(C)C)CC1N1C2=NC(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=CN=C2C=C1 VVNOZVPEJKGAJI-RMKNXTFCSA-N 0.000 description 4
- RSIVIGHVQATMNW-RMKNXTFCSA-N (e)-4-(dimethylamino)-1-[3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]but-2-en-1-one Chemical compound C1N(C(=O)/C=C/CN(C)C)CC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 RSIVIGHVQATMNW-RMKNXTFCSA-N 0.000 description 4
- HOGVMRPGJIMKOP-RMKNXTFCSA-N (e)-4-(dimethylamino)-1-[3-[6-(4-phenoxyphenyl)pyrrolo[3,2-b]pyridin-1-yl]azetidin-1-yl]but-2-en-1-one Chemical compound C1N(C(=O)/C=C/CN(C)C)CC1N1C2=CC(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=CN=C2C=C1 HOGVMRPGJIMKOP-RMKNXTFCSA-N 0.000 description 4
- ITIGJTVWYCLBIR-RMKNXTFCSA-N (e)-4-(dimethylamino)-1-[4-[7-(4-phenoxyphenoxy)pyrazolo[4,3-d]pyrimidin-1-yl]piperidin-1-yl]but-2-en-1-one Chemical compound C1CN(C(=O)/C=C/CN(C)C)CCC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=N1 ITIGJTVWYCLBIR-RMKNXTFCSA-N 0.000 description 4
- XQTIHILHJPULOA-SNAWJCMRSA-N (e)-4-[4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]piperazin-1-yl]but-2-enoic acid Chemical compound CC(C)(C)OC(=O)NCCN1CCN(C\C=C\C(O)=O)CC1 XQTIHILHJPULOA-SNAWJCMRSA-N 0.000 description 4
- RHHLCHSKUBYBNK-GOSISDBHSA-N 1-[(2r)-2-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]azetidin-1-yl]prop-2-en-1-one Chemical compound C=CC(=O)N1CC[C@@H]1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 RHHLCHSKUBYBNK-GOSISDBHSA-N 0.000 description 4
- RHHLCHSKUBYBNK-SFHVURJKSA-N 1-[(2s)-2-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]azetidin-1-yl]prop-2-en-1-one Chemical compound C=CC(=O)N1CC[C@H]1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 RHHLCHSKUBYBNK-SFHVURJKSA-N 0.000 description 4
- IROPLOFUURMPNM-UHFFFAOYSA-N 1-[3-[3-(4-phenoxyphenyl)pyrrolo[2,3-b]pyrazin-5-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC1N1C2=NC(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=CN=C2C=C1 IROPLOFUURMPNM-UHFFFAOYSA-N 0.000 description 4
- IAUZUOFHAKBZML-UHFFFAOYSA-N 1-[3-[4-(1-benzylpyrazol-4-yl)oxypyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC1N1C2=C(OC3=CN(CC=4C=CC=CC=4)N=C3)N=CN=C2C=C1 IAUZUOFHAKBZML-UHFFFAOYSA-N 0.000 description 4
- MGZFXTWNQDNUQK-UHFFFAOYSA-N 1-[3-[4-(4-benzylphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC1N1C2=C(OC=3C=CC(CC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 MGZFXTWNQDNUQK-UHFFFAOYSA-N 0.000 description 4
- SJKUBFJGXOIWMH-UHFFFAOYSA-N 1-[3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 SJKUBFJGXOIWMH-UHFFFAOYSA-N 0.000 description 4
- GHFAFDXPDVUSPU-UHFFFAOYSA-N 1-[4-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]piperidin-1-yl]prop-2-en-1-one Chemical compound C1CN(C(=O)C=C)CCC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 GHFAFDXPDVUSPU-UHFFFAOYSA-N 0.000 description 4
- SBBYJOMVLFKMMC-UHFFFAOYSA-N 1-[6-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC11CC(N2C3=C(OC=4C=CC(OC=5C=CC=CC=5)=CC=4)N=CN=C3C=C2)C1 SBBYJOMVLFKMMC-UHFFFAOYSA-N 0.000 description 4
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 4
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 4
- ANGPSTDEZFSYDC-UHFFFAOYSA-N 2-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]azetidine-1-carbonitrile Chemical compound N#CN1CCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 ANGPSTDEZFSYDC-UHFFFAOYSA-N 0.000 description 4
- ZFEUTOCIFOLXRS-UHFFFAOYSA-N 2-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidine-1-carbonitrile Chemical compound N#CN1CCCCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 ZFEUTOCIFOLXRS-UHFFFAOYSA-N 0.000 description 4
- FGBVZOFOIZLLJX-UHFFFAOYSA-N 2-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 FGBVZOFOIZLLJX-UHFFFAOYSA-N 0.000 description 4
- FKHUHIOLKNXMIT-UHFFFAOYSA-N 2-methyl-1-[3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C(=C)C)CC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 FKHUHIOLKNXMIT-UHFFFAOYSA-N 0.000 description 4
- QDIPVXCECCURPG-QPJJXVBHSA-N 3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]-n-[2-[4-[(e)-4-oxo-4-[4-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]piperidin-1-yl]but-2-enyl]piperazin-1-yl]ethyl]propanamide Chemical compound C1CN(CCNC(=O)CCOCCOCCOCCOCCN)CCN1C\C=C\C(=O)N1CCC(N2C3=C(OC=4C=CC(OC=5C=CC=CC=5)=CC=4)N=CN=C3C=C2)CC1 QDIPVXCECCURPG-QPJJXVBHSA-N 0.000 description 4
- NHNPAJMAICNQGF-UHFFFAOYSA-N 3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidine-1-carbonitrile Chemical compound C1N(C#N)CC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 NHNPAJMAICNQGF-UHFFFAOYSA-N 0.000 description 4
- QOXRADRCLNDUBQ-UHFFFAOYSA-N 3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]piperidine-1-carbonitrile Chemical compound C1N(C#N)CCCC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 QOXRADRCLNDUBQ-UHFFFAOYSA-N 0.000 description 4
- OSFJKMHWEQDBER-UHFFFAOYSA-N 3-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]azetidine-1-carbonitrile Chemical compound C1N(C#N)CC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 OSFJKMHWEQDBER-UHFFFAOYSA-N 0.000 description 4
- UJJHJGFGSNHDQY-UHFFFAOYSA-N 3-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidine-1-carbonitrile Chemical compound C1N(C#N)CCCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 UJJHJGFGSNHDQY-UHFFFAOYSA-N 0.000 description 4
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 4
- RTAOXGCLVOCYOD-UHFFFAOYSA-N 3-methyl-1-[3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]but-2-en-1-one Chemical compound C1N(C(=O)C=C(C)C)CC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 RTAOXGCLVOCYOD-UHFFFAOYSA-N 0.000 description 4
- VCKSLBYNQIXHNA-UHFFFAOYSA-N 4-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidine-1-carbonitrile Chemical compound C1CN(C#N)CCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 VCKSLBYNQIXHNA-UHFFFAOYSA-N 0.000 description 4
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 4
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 4
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 4
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 4
- XAGDADRYFBJGSJ-MXVIHJGJSA-N C=CC(=O)N[C@H]1CC[C@@H](CC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C=CC(=O)N[C@H]1CC[C@@H](CC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 XAGDADRYFBJGSJ-MXVIHJGJSA-N 0.000 description 4
- DLJJVJHSXWNVBL-IYARVYRRSA-N C=CC(=O)N[C@H]1C[C@@H](C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C=CC(=O)N[C@H]1C[C@@H](C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 DLJJVJHSXWNVBL-IYARVYRRSA-N 0.000 description 4
- DLJJVJHSXWNVBL-HDICACEKSA-N C=CC(=O)N[C@H]1C[C@H](C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C=CC(=O)N[C@H]1C[C@H](C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 DLJJVJHSXWNVBL-HDICACEKSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- CSVGKPXDIQVMKI-UHFFFAOYSA-N O(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CN=C2C(=N1)N(N=C2)C1CN(C1)C(C=C)=O Chemical compound O(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CN=C2C(=N1)N(N=C2)C1CN(C1)C(C=C)=O CSVGKPXDIQVMKI-UHFFFAOYSA-N 0.000 description 4
- FGSZABJFBAXYGN-GOSISDBHSA-N O(C1=CC=CC=C1)C1=CC=C(OC=2C3=C(N=CN=2)C=CN3[C@H]2CN(CC2)C(C=C)=O)C=C1 Chemical compound O(C1=CC=CC=C1)C1=CC=C(OC=2C3=C(N=CN=2)C=CN3[C@H]2CN(CC2)C(C=C)=O)C=C1 FGSZABJFBAXYGN-GOSISDBHSA-N 0.000 description 4
- OAQHNXXNVKYHCC-UHFFFAOYSA-N O(C1=CC=CC=C1)C=1C=C(C=CC=1)C=1C2=C(N=CN=1)C=CN2C1CCN(CC1)C(C=C)=O Chemical compound O(C1=CC=CC=C1)C=1C=C(C=CC=1)C=1C2=C(N=CN=1)C=CN2C1CCN(CC1)C(C=C)=O OAQHNXXNVKYHCC-UHFFFAOYSA-N 0.000 description 4
- 0 Oc1cc(Oc2cc(O)ccc2C2(c(c3c4)ccc4C(NCCCCCC(*CCN4CCN(CC=CC(N(C5)CC5[n](ccc5ncn6)c5c6Oc(cc5)ccc5Oc5ccccc5)=O)CC4)=O)=O)OC3=O)c2cc1 Chemical compound Oc1cc(Oc2cc(O)ccc2C2(c(c3c4)ccc4C(NCCCCCC(*CCN4CCN(CC=CC(N(C5)CC5[n](ccc5ncn6)c5c6Oc(cc5)ccc5Oc5ccccc5)=O)CC4)=O)=O)OC3=O)c2cc1 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- KCSKCIQYNAOBNQ-YBSFLMRUSA-N biotin sulfoxide Chemical compound N1C(=O)N[C@H]2CS(=O)[C@@H](CCCCC(=O)O)[C@H]21 KCSKCIQYNAOBNQ-YBSFLMRUSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- BGOABHZFDOFQAM-UHFFFAOYSA-N n-[2-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]prop-2-enamide Chemical compound C=12N(CCNC(=O)C=C)C=CC2=NC=NC=1OC(C=C1)=CC=C1OC1=CC=CC=C1 BGOABHZFDOFQAM-UHFFFAOYSA-N 0.000 description 4
- HNEJYGXAJMNRLB-UHFFFAOYSA-N n-[3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]propyl]prop-2-enamide Chemical compound C=12N(CCCNC(=O)C=C)C=CC2=NC=NC=1OC(C=C1)=CC=C1OC1=CC=CC=C1 HNEJYGXAJMNRLB-UHFFFAOYSA-N 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000001422 pyrrolinyl group Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229940043267 rhodamine b Drugs 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- XPDIKRMPZNLBAC-UHFFFAOYSA-N tert-butyl 3-iodoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(I)C1 XPDIKRMPZNLBAC-UHFFFAOYSA-N 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- ONGHCCOEHRLASK-QGZVFWFLSA-N (3r)-3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]pyrrolidine-1-carbonitrile Chemical compound C1N(C#N)CC[C@H]1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 ONGHCCOEHRLASK-QGZVFWFLSA-N 0.000 description 3
- OACOEOMXRORVQN-JLXBBBJOSA-N (e)-4-(dimethylamino)-1-[(3s)-3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]pyrrolidin-1-yl]but-2-en-1-one Chemical compound C1N(C(=O)/C=C/CN(C)C)CC[C@@H]1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 OACOEOMXRORVQN-JLXBBBJOSA-N 0.000 description 3
- UUHNQHFOIVLAQX-BJILWQEISA-N (e)-4-(dimethylamino)but-2-enoic acid;hydrochloride Chemical compound Cl.CN(C)C\C=C\C(O)=O UUHNQHFOIVLAQX-BJILWQEISA-N 0.000 description 3
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 3
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 3
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 3
- IGZZCOJQPDOAEM-UHFFFAOYSA-N 1-[4-[7-(4-phenoxyphenoxy)pyrazolo[4,3-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one Chemical compound C1CN(C(=O)C=C)CCC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=N1 IGZZCOJQPDOAEM-UHFFFAOYSA-N 0.000 description 3
- 125000005955 1H-indazolyl group Chemical group 0.000 description 3
- JOCWQJGZBIFQLM-UHFFFAOYSA-N 3-bromo-5h-pyrrolo[2,3-b]pyrazine Chemical compound BrC1=CN=C2C=CNC2=N1 JOCWQJGZBIFQLM-UHFFFAOYSA-N 0.000 description 3
- VXTBVHDVOPKHET-YRNVUSSQSA-N 6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]-n-[2-[4-[(e)-4-oxo-4-[3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]but-2-enyl]piperazin-1-yl]ethyl]hexanamide Chemical compound C12=NON=C2C([N+](=O)[O-])=CC=C1NCCCCCC(=O)NCCN(CC1)CCN1C\C=C\C(=O)N(C1)CC1N(C=12)C=CC2=NC=NC=1OC(C=C1)=CC=C1OC1=CC=CC=C1 VXTBVHDVOPKHET-YRNVUSSQSA-N 0.000 description 3
- PNEVJAHXDJISOJ-UHFFFAOYSA-N 6-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]-2-azaspiro[3.3]heptane-2-carbonitrile Chemical compound C1N(C#N)CC11CC(N2C3=C(OC=4C=CC(OC=5C=CC=CC=5)=CC=4)N=CN=C3C=C2)C1 PNEVJAHXDJISOJ-UHFFFAOYSA-N 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- LCJYMULNVASIMJ-UHFFFAOYSA-N C(C1=CC=CC=C1)N1N=CC(=C1)N1C2=C(N=CC1)N(C=C2)C2CN(C2)C=CC=O Chemical compound C(C1=CC=CC=C1)N1N=CC(=C1)N1C2=C(N=CC1)N(C=C2)C2CN(C2)C=CC=O LCJYMULNVASIMJ-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- IXQIUDNVFVTQLJ-UHFFFAOYSA-N Naphthofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=C2C=CC2=CC(O)=CC=C21 IXQIUDNVFVTQLJ-UHFFFAOYSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- HTRRPYMXRSBBOF-UHFFFAOYSA-N O(C1=CC=CC=C1)C1=CC=C(OC=2C3=C(N=CN2)C=CN3CC3CN(CCC3)C(C=CC)=O)C=C1 Chemical compound O(C1=CC=CC=C1)C1=CC=C(OC=2C3=C(N=CN2)C=CN3CC3CN(CCC3)C(C=CC)=O)C=C1 HTRRPYMXRSBBOF-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 125000002393 azetidinyl group Chemical group 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- PTIUZRZHZRYCJE-UHFFFAOYSA-N cascade yellow Chemical compound C1=C(S([O-])(=O)=O)C(OC)=CC=C1C1=CN=C(C=2C=C[N+](CC=3C=C(C=CC=3)C(=O)ON3C(CCC3=O)=O)=CC=2)O1 PTIUZRZHZRYCJE-UHFFFAOYSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 125000004431 deuterium atom Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 125000003838 furazanyl group Chemical group 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 125000002636 imidazolinyl group Chemical group 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 3
- 125000004926 indolenyl group Chemical group 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- VAPIQEBDFQQCLJ-UHFFFAOYSA-N n-cyano-4-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]piperidine-1-carboxamide Chemical compound C1CN(C(NC#N)=O)CCC1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 VAPIQEBDFQQCLJ-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 125000003566 oxetanyl group Chemical group 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000007856 photoaffinity label Substances 0.000 description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 3
- 125000002755 pyrazolinyl group Chemical group 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- WSUMHFNEPOYLJM-UHFFFAOYSA-N tert-butyl n-(3-hydroxycyclobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CC(O)C1 WSUMHFNEPOYLJM-UHFFFAOYSA-N 0.000 description 3
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- FGSZABJFBAXYGN-SFHVURJKSA-N 1-[(3s)-3-[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC[C@@H]1N1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 FGSZABJFBAXYGN-SFHVURJKSA-N 0.000 description 2
- BVMNKBKYKGSZSZ-UHFFFAOYSA-N 1-[3-[4-(4-anilinophenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC1N1C2=C(OC=3C=CC(NC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 BVMNKBKYKGSZSZ-UHFFFAOYSA-N 0.000 description 2
- VITYSQBDYZKYLA-UHFFFAOYSA-N 1-[3-[4-(4-phenoxyanilino)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC1N1C2=C(NC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 VITYSQBDYZKYLA-UHFFFAOYSA-N 0.000 description 2
- QEXDRBSUJPMSFM-UHFFFAOYSA-N 1-[3-[4-(4-phenylmethoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC1N1C2=C(OC=3C=CC(OCC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 QEXDRBSUJPMSFM-UHFFFAOYSA-N 0.000 description 2
- RMAGFPJWGPQZRJ-UHFFFAOYSA-N 1-[3-[[4-(3-phenoxyphenyl)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CCCC1CN1C2=C(C=3C=C(OC=4C=CC=CC=4)C=CC=3)N=CN=C2C=C1 RMAGFPJWGPQZRJ-UHFFFAOYSA-N 0.000 description 2
- QFZKPPBBJLKKMU-UHFFFAOYSA-N 1-[3-[[4-(3-phenoxyphenyl)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CCC1CN1C2=C(C=3C=C(OC=4C=CC=CC=4)C=CC=3)N=CN=C2C=C1 QFZKPPBBJLKKMU-UHFFFAOYSA-N 0.000 description 2
- MBCIROMESHTQBJ-UHFFFAOYSA-N 1-[3-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]azetidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 MBCIROMESHTQBJ-UHFFFAOYSA-N 0.000 description 2
- KJBXDOUPYYLUCG-UHFFFAOYSA-N 1-[3-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CCCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 KJBXDOUPYYLUCG-UHFFFAOYSA-N 0.000 description 2
- DBIGFLCHGRUYPI-UHFFFAOYSA-N 1-[3-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 DBIGFLCHGRUYPI-UHFFFAOYSA-N 0.000 description 2
- ZCQKTBUCLUMTAU-UHFFFAOYSA-N 1-[3-[[4-(4-phenoxyphenyl)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidin-1-yl]prop-2-en-1-one Chemical compound C1N(C(=O)C=C)CCCC1CN1C2=C(C=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 ZCQKTBUCLUMTAU-UHFFFAOYSA-N 0.000 description 2
- SFKBVYONXFQMBD-UHFFFAOYSA-N 1-[4-[[4-(3-phenoxyphenyl)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidin-1-yl]prop-2-en-1-one Chemical compound C1CN(C(=O)C=C)CCC1CN1C2=C(C=3C=C(OC=4C=CC=CC=4)C=CC=3)N=CN=C2C=C1 SFKBVYONXFQMBD-UHFFFAOYSA-N 0.000 description 2
- YZSRCWIOBANGCW-UHFFFAOYSA-N 1-[4-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidin-1-yl]prop-2-en-1-one Chemical compound C1CN(C(=O)C=C)CCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 YZSRCWIOBANGCW-UHFFFAOYSA-N 0.000 description 2
- VCHQPZOQAVEWRW-UHFFFAOYSA-N 1-[4-[[4-(4-phenoxyphenyl)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidin-1-yl]prop-2-en-1-one Chemical compound C1CN(C(=O)C=C)CCC1CN1C2=C(C=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 VCHQPZOQAVEWRW-UHFFFAOYSA-N 0.000 description 2
- KALGJSAOBMDTIS-UHFFFAOYSA-N 1-tert-butyl-3-iodoazetidine Chemical compound CC(C)(C)N1CC(I)C1 KALGJSAOBMDTIS-UHFFFAOYSA-N 0.000 description 2
- JNGRENQDBKMCCR-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)benzoic acid;hydrochloride Chemical compound [Cl-].C=12C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O JNGRENQDBKMCCR-UHFFFAOYSA-N 0.000 description 2
- RUVJFMSQTCEAAB-UHFFFAOYSA-M 2-[3-[5,6-dichloro-1,3-bis[[4-(chloromethyl)phenyl]methyl]benzimidazol-2-ylidene]prop-1-enyl]-3-methyl-1,3-benzoxazol-3-ium;chloride Chemical compound [Cl-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C(N(C1=CC(Cl)=C(Cl)C=C11)CC=2C=CC(CCl)=CC=2)N1CC1=CC=C(CCl)C=C1 RUVJFMSQTCEAAB-UHFFFAOYSA-M 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 2
- WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- UWROBKHIEKWFAJ-UHFFFAOYSA-N 6-chloro-1h-pyrrolo[3,2-b]pyridine Chemical compound ClC1=CN=C2C=CNC2=C1 UWROBKHIEKWFAJ-UHFFFAOYSA-N 0.000 description 2
- DJFNQJJTTPMBIL-UHFFFAOYSA-N 7-nitrobenzoxadiazole-6-aminohexanoic acid Chemical compound OC(=O)CCCCCNC1=CC=C([N+]([O-])=O)C2=NON=C12 DJFNQJJTTPMBIL-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 239000012104 Alexa Fluor 500 Substances 0.000 description 2
- 239000012109 Alexa Fluor 568 Substances 0.000 description 2
- 239000012110 Alexa Fluor 594 Substances 0.000 description 2
- 239000012112 Alexa Fluor 633 Substances 0.000 description 2
- 239000012115 Alexa Fluor 660 Substances 0.000 description 2
- 239000012116 Alexa Fluor 680 Substances 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- BGXCDXYBUUKOKC-UHFFFAOYSA-N C(C1=CC=CC=C1)N1N=CC(=C1)C1=CN=C2C(=N1)N(C=C2)C1CN(C1)C(C=C)=O Chemical compound C(C1=CC=CC=C1)N1N=CC(=C1)C1=CN=C2C(=N1)N(C=C2)C1CN(C1)C(C=C)=O BGXCDXYBUUKOKC-UHFFFAOYSA-N 0.000 description 2
- XKZVYZBSSLTEBL-UHFFFAOYSA-N C(C1CCCN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C(C1CCCN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 XKZVYZBSSLTEBL-UHFFFAOYSA-N 0.000 description 2
- RJHDSQMXAMFNGA-UHFFFAOYSA-N C1CC(CCN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C1CC(CCN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 RJHDSQMXAMFNGA-UHFFFAOYSA-N 0.000 description 2
- ORPLRHRWOJMPBY-JXMROGBWSA-N C1CN(CCNC(=O)CCOCCOCCOCCOCCNC(=O)OC(C)(C)C)CCN1C\C=C\C(=O)N1CCC(n2ccc3ncnc(Oc4ccc(Oc5ccccc5)cc4)c32)CC1 Chemical compound C1CN(CCNC(=O)CCOCCOCCOCCOCCNC(=O)OC(C)(C)C)CCN1C\C=C\C(=O)N1CCC(n2ccc3ncnc(Oc4ccc(Oc5ccccc5)cc4)c32)CC1 ORPLRHRWOJMPBY-JXMROGBWSA-N 0.000 description 2
- XNHAMARKSVMDLM-UHFFFAOYSA-N C1COC2(CCC(CC2)n2ccc3ncnc(Oc4ccc(Oc5ccccc5)cc4)c23)O1 Chemical compound C1COC2(CCC(CC2)n2ccc3ncnc(Oc4ccc(Oc5ccccc5)cc4)c23)O1 XNHAMARKSVMDLM-UHFFFAOYSA-N 0.000 description 2
- CXWXNQAQUBMSNB-UHFFFAOYSA-N CC(C)(C)N1CC(Br)C1 Chemical compound CC(C)(C)N1CC(Br)C1 CXWXNQAQUBMSNB-UHFFFAOYSA-N 0.000 description 2
- HOYPGALLCCRKRX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC1)n1ncc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1ncc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 HOYPGALLCCRKRX-UHFFFAOYSA-N 0.000 description 2
- ULAHASTXHCQCME-UHFFFAOYSA-N CNC1CCC(CC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound CNC1CCC(CC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 ULAHASTXHCQCME-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000132536 Cirsium Species 0.000 description 2
- DHECDCRBODCRKI-UHFFFAOYSA-N Cl.C1CC(CCN1)n1ncc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound Cl.C1CC(CCN1)n1ncc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 DHECDCRBODCRKI-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- PDKDKIZVZVKGTP-UHFFFAOYSA-N DY-485XL Chemical compound O=C1OC2=CC(N(CCCCCC(O)=O)CC)=CC=C2C=C1C1=CC=[N+](CCCS([O-])(=O)=O)C=C1 PDKDKIZVZVKGTP-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- UVLPMZUJSRTQKV-UHFFFAOYSA-N N(c1ccc(Oc2ccccc2)cc1)c1ncnc2cc[nH]c12 Chemical compound N(c1ccc(Oc2ccccc2)cc1)c1ncnc2cc[nH]c12 UVLPMZUJSRTQKV-UHFFFAOYSA-N 0.000 description 2
- XJCJXSPIEIOVOE-UHFFFAOYSA-N N,N-bis(2,4,6-trimethylphenyl)-3,4:9,10-perylenebis(dicarboximide) Chemical compound CC1=CC(C)=CC(C)=C1N(C(=O)C=1C2=C3C4=CC=1)C(=O)C2=CC=C3C(C=C1)=C2C4=CC=C3C(=O)N(C=4C(=CC(C)=CC=4C)C)C(=O)C1=C23 XJCJXSPIEIOVOE-UHFFFAOYSA-N 0.000 description 2
- UQKBNAHETWFALR-QPJJXVBHSA-N NCCN1CCN(CC1)C/C=C/C(=O)N1CCC(CC1)N1C=CC=2N=CN=C(C21)OC2=CC=C(C=C2)OC2=CC=CC=C2 Chemical compound NCCN1CCN(CC1)C/C=C/C(=O)N1CCC(CC1)N1C=CC=2N=CN=C(C21)OC2=CC=C(C=C2)OC2=CC=CC=C2 UQKBNAHETWFALR-QPJJXVBHSA-N 0.000 description 2
- OQHJTCBZPZXKCD-UHFFFAOYSA-N O(C1=CC=CC=C1)C1=CC=C(C=C1)C=1C2=C(N=CN=1)C=CN2CC1CN(CC1)C(C=C)=O Chemical compound O(C1=CC=CC=C1)C1=CC=C(C=C1)C=1C2=C(N=CN=1)C=CN2CC1CN(CC1)C(C=C)=O OQHJTCBZPZXKCD-UHFFFAOYSA-N 0.000 description 2
- UQKJPWCGYSZBEI-UHFFFAOYSA-N O(c1ccccc1)c1ccc(Oc2ncnc3cn[nH]c23)cc1 Chemical compound O(c1ccccc1)c1ccc(Oc2ncnc3cn[nH]c23)cc1 UQKJPWCGYSZBEI-UHFFFAOYSA-N 0.000 description 2
- CNWIPKYKVUWVSM-UHFFFAOYSA-N O(c1ccccc1)c1ccc(cc1)-c1ncnc2cc[nH]c12 Chemical compound O(c1ccccc1)c1ccc(cc1)-c1ncnc2cc[nH]c12 CNWIPKYKVUWVSM-UHFFFAOYSA-N 0.000 description 2
- JTKYBTDKTLEGHI-UHFFFAOYSA-N O=C(CC#N)N1CCC(CC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound O=C(CC#N)N1CCC(CC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 JTKYBTDKTLEGHI-UHFFFAOYSA-N 0.000 description 2
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 2
- SHHVXLLZGMQNMA-UHFFFAOYSA-N OOC(=O)N1CCC1 Chemical compound OOC(=O)N1CCC1 SHHVXLLZGMQNMA-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035742 Pneumonitis Diseases 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 2
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 239000007801 affinity label Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000005512 benztetrazolyl group Chemical group 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 150000001615 biotins Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- AWLOVEGGARHZNN-UHFFFAOYSA-N butyl 3-hydroxypyrrolidine-1-carboxylate Chemical compound CCCCOC(=O)N1CCC(O)C1 AWLOVEGGARHZNN-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OKIIEJOIXGHUKX-UHFFFAOYSA-L cadmium iodide Chemical compound [Cd+2].[I-].[I-] OKIIEJOIXGHUKX-UHFFFAOYSA-L 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000004623 carbolinyl group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- KCDCNGXPPGQERR-UHFFFAOYSA-N coumarin 343 Chemical compound C1CCC2=C(OC(C(C(=O)O)=C3)=O)C3=CC3=C2N1CCC3 KCDCNGXPPGQERR-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 2
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229910052876 emerald Inorganic materials 0.000 description 2
- 239000010976 emerald Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- 229940011411 erythrosine Drugs 0.000 description 2
- 239000004174 erythrosine Substances 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- UKZQEOHHLOYJLY-UHFFFAOYSA-M ethyl eosin Chemical compound [K+].CCOC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 UKZQEOHHLOYJLY-UHFFFAOYSA-M 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- KCPRYVGBEBFLIG-UHFFFAOYSA-N fluorescein bis-arsenide Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=CC(=O)C([As]3SCCS3)=C2OC2=C([As]3SCCS3)C(O)=CC=C21 KCPRYVGBEBFLIG-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 150000002344 gold compounds Chemical class 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 2
- 125000005438 isoindazolyl group Chemical group 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 230000005445 isotope effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- XFKVYXCRNATCOO-UHFFFAOYSA-M rhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC=CC=C1C(=O)OCC XFKVYXCRNATCOO-UHFFFAOYSA-M 0.000 description 2
- 150000003873 salicylate salts Chemical group 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- ZSOMPVKQDGLTOT-UHFFFAOYSA-J sodium green Chemical compound C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.COC=1C=C(NC(=O)C=2C=C(C(=CC=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C([O-])=O)C(OC)=CC=1N(CCOCC1)CCOCCOCCN1C(C(=C1)OC)=CC(OC)=C1NC(=O)C1=CC=C(C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C(C([O-])=O)=C1 ZSOMPVKQDGLTOT-UHFFFAOYSA-J 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OJCLHERKFHHUTB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(CO)C1 OJCLHERKFHHUTB-UHFFFAOYSA-N 0.000 description 2
- RUTPPPNQDPSSBM-UHFFFAOYSA-N tert-butyl 3-bromoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(Br)C1 RUTPPPNQDPSSBM-UHFFFAOYSA-N 0.000 description 2
- XRRXRQJQQKMFBC-UHFFFAOYSA-N tert-butyl 3-hydroxyazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C1 XRRXRQJQQKMFBC-UHFFFAOYSA-N 0.000 description 2
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- XJIVDAWUVXYEHF-YRNVUSSQSA-N (e)-4-(dimethylamino)-1-[3-[[4-(4-phenoxyphenoxy)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]piperidin-1-yl]but-2-en-1-one Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC1CN1C2=C(OC=3C=CC(OC=4C=CC=CC=4)=CC=3)N=CN=C2C=C1 XJIVDAWUVXYEHF-YRNVUSSQSA-N 0.000 description 1
- DOTGZROJTAUYFQ-OWOJBTEDSA-N (e)-4-bromobut-2-enoic acid Chemical compound OC(=O)\C=C\CBr DOTGZROJTAUYFQ-OWOJBTEDSA-N 0.000 description 1
- RLYNGYDVXRKEOO-XQHVRGAUSA-N (e)-but-2-enoic acid Chemical compound C\C=C\C(O)=O.C\C=C\C(O)=O RLYNGYDVXRKEOO-XQHVRGAUSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- MUCPGEPGWYOKRO-UHFFFAOYSA-N 1,3,2-diazaborinine Chemical compound B1=NC=CC=N1 MUCPGEPGWYOKRO-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical group C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- HKQTYQDNCKMNHZ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-ol Chemical compound C1CC(O)CCC21OCCO2 HKQTYQDNCKMNHZ-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- ZVPORPUUZXIPEF-UHFFFAOYSA-N 1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC=2C=CC=CC=2)N=C1 ZVPORPUUZXIPEF-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- KAUABWYBFARJAF-UHFFFAOYSA-N 1h-pyrazol-4-ol Chemical compound OC=1C=NNC=1 KAUABWYBFARJAF-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical group C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- LCZASQOOGUQRIA-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane Chemical compound CCCP1OP(CCC)OP(CCC)O1 LCZASQOOGUQRIA-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- GMPMGSCJCDAUMP-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;lead(2+);trihydrate Chemical compound O.O.O.[Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O GMPMGSCJCDAUMP-UHFFFAOYSA-H 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- YEIYIPDFZMLJQH-UHFFFAOYSA-N 3-[2-[2-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCOCCOCCOCCOCCC(O)=O YEIYIPDFZMLJQH-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- WGLQHUKCXBXUDV-UHFFFAOYSA-L 3-aminophthalate Chemical compound NC1=CC=CC(C([O-])=O)=C1C([O-])=O WGLQHUKCXBXUDV-UHFFFAOYSA-L 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- BDUBTLFQHNYXPC-UHFFFAOYSA-N 3-methylbut-2-enoyl chloride Chemical compound CC(C)=CC(Cl)=O BDUBTLFQHNYXPC-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical group C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KIVFDFJTCRMULF-UHFFFAOYSA-N 4-(4-fluorophenoxy)phenol Chemical compound C1=CC(O)=CC=C1OC1=CC=C(F)C=C1 KIVFDFJTCRMULF-UHFFFAOYSA-N 0.000 description 1
- HJSPWKGEPDZNLK-UHFFFAOYSA-N 4-benzylphenol Chemical compound C1=CC(O)=CC=C1CC1=CC=CC=C1 HJSPWKGEPDZNLK-UHFFFAOYSA-N 0.000 description 1
- JTTMYKSFKOOQLP-UHFFFAOYSA-N 4-hydroxydiphenylamine Chemical compound C1=CC(O)=CC=C1NC1=CC=CC=C1 JTTMYKSFKOOQLP-UHFFFAOYSA-N 0.000 description 1
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical group C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical group C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- PGTUKZWBYWVLHW-UHFFFAOYSA-N 6-chloro-1h-pyrazolo[3,4-b]pyrazine Chemical compound ClC1=CN=C2C=NNC2=N1 PGTUKZWBYWVLHW-UHFFFAOYSA-N 0.000 description 1
- AOSJWPZJQOIPIU-UHFFFAOYSA-N 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylic acid Chemical compound C1C(O)CC21CN(C(O)=O)C2 AOSJWPZJQOIPIU-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- GZFKJMWBKTUNJS-UHFFFAOYSA-N 7-benzylamino-4-nitrobenz-2-oxa-1,3-diazole Chemical compound C12=NON=C2C([N+](=O)[O-])=CC=C1NCC1=CC=CC=C1 GZFKJMWBKTUNJS-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 208000023611 Burkitt leukaemia Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- NNVPNXAGTRTZAW-UHFFFAOYSA-N C(C1CCCNC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C(C1CCCNC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 NNVPNXAGTRTZAW-UHFFFAOYSA-N 0.000 description 1
- BQZGYZORSYGOIU-UHFFFAOYSA-N C(C1CCN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C(C1CCN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 BQZGYZORSYGOIU-UHFFFAOYSA-N 0.000 description 1
- QPTBTYLDPMABBT-UHFFFAOYSA-N C(C1CCNC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C(C1CCNC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 QPTBTYLDPMABBT-UHFFFAOYSA-N 0.000 description 1
- ICFBFNWNQUTCMH-UHFFFAOYSA-N C(C1CCNCC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C(C1CCNCC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 ICFBFNWNQUTCMH-UHFFFAOYSA-N 0.000 description 1
- FTUYRIAKFPAQOE-UHFFFAOYSA-N C(C1CNC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C(C1CNC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 FTUYRIAKFPAQOE-UHFFFAOYSA-N 0.000 description 1
- KSNPOJKUJHRGTQ-UHFFFAOYSA-N C1CC(CN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C1CC(CN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 KSNPOJKUJHRGTQ-UHFFFAOYSA-N 0.000 description 1
- BZEMGLJFXYRSGY-JXMROGBWSA-N C1CN(CCNC(=O)OC(C)(C)C)CCN1C\C=C\C(=O)N1CCC(n2ccc3ncnc(Oc4ccc(Oc5ccccc5)cc4)c32)CC1 Chemical compound C1CN(CCNC(=O)OC(C)(C)C)CCN1C\C=C\C(=O)N1CCC(n2ccc3ncnc(Oc4ccc(Oc5ccccc5)cc4)c32)CC1 BZEMGLJFXYRSGY-JXMROGBWSA-N 0.000 description 1
- HHSTWFTZIRUGAU-UHFFFAOYSA-N C1CNCC(C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C1CNCC(C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 HHSTWFTZIRUGAU-UHFFFAOYSA-N 0.000 description 1
- KSNPOJKUJHRGTQ-INIZCTEOSA-N C1C[C@@H](CN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C1C[C@@H](CN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 KSNPOJKUJHRGTQ-INIZCTEOSA-N 0.000 description 1
- KSNPOJKUJHRGTQ-MRXNPFEDSA-N C1C[C@H](CN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C1C[C@H](CN1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 KSNPOJKUJHRGTQ-MRXNPFEDSA-N 0.000 description 1
- RNVRMHZEKHGENS-UHFFFAOYSA-N C1NCC11CC(C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound C1NCC11CC(C1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 RNVRMHZEKHGENS-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- BXHXWQZFQZUASV-UHFFFAOYSA-N C=CC(N1CC(CN2C=Cc3ncnc(Oc(cc4)ccc4Oc4ccccc4)c3C2)CCC1)=O Chemical compound C=CC(N1CC(CN2C=Cc3ncnc(Oc(cc4)ccc4Oc4ccccc4)c3C2)CCC1)=O BXHXWQZFQZUASV-UHFFFAOYSA-N 0.000 description 1
- JMGSBFFFUBQGAB-UHFFFAOYSA-N C=CC(NCC[n](ccc1ncn2)c1c2Oc(cc1)ccc1Oc1ccccc1)O Chemical compound C=CC(NCC[n](ccc1ncn2)c1c2Oc(cc1)ccc1Oc1ccccc1)O JMGSBFFFUBQGAB-UHFFFAOYSA-N 0.000 description 1
- RJMLJJDJJIXSQX-UHFFFAOYSA-N CCCN1CCN(CCNC(CCCCCNC(c2ccc(C3(c(ccc(O)c4)c4Oc4c3ccc(O)c4)OC3=O)c3c2)=O)=O)CC1 Chemical compound CCCN1CCN(CCNC(CCCCCNC(c2ccc(C3(c(ccc(O)c4)c4Oc4c3ccc(O)c4)OC3=O)c3c2)=O)=O)CC1 RJMLJJDJJIXSQX-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- JXGAYLBTGAVHQN-UHFFFAOYSA-N CNCC=C=S(N=C)=[O]C Chemical compound CNCC=C=S(N=C)=[O]C JXGAYLBTGAVHQN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010057254 Connective tissue inflammation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101000868789 Drosophila melanogaster Carboxypeptidase D Proteins 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- PSCMQHVBLHHWTO-UHFFFAOYSA-K Indium trichloride Inorganic materials Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- WHRIJJNMHNYUNG-UHFFFAOYSA-N O1CCOC12CCC(CC2)=O.O2CCOC21CCC(CC1)O Chemical compound O1CCOC12CCC(CC2)=O.O2CCOC21CCC(CC1)O WHRIJJNMHNYUNG-UHFFFAOYSA-N 0.000 description 1
- CLCUCHGPIYRFBQ-UHFFFAOYSA-N O=C1CCC(CC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 Chemical compound O=C1CCC(CC1)n1ccc2ncnc(Oc3ccc(Oc4ccccc4)cc3)c12 CLCUCHGPIYRFBQ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Natural products C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 229910052770 Uranium Chemical group 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HGMCCUMQECCTMA-UHFFFAOYSA-N [Ag].C1(=CC=CC=C1)C1=C2C=CC(C(=C3C=CC(=C(C=4C=CC(=C(C5=CC=C1N5)C5=CC=CC=C5)N4)C4=CC=CC=C4)N3)C3=CC=CC=C3)=N2 Chemical compound [Ag].C1(=CC=CC=C1)C1=C2C=CC(C(=C3C=CC(=C(C=4C=CC(=C(C5=CC=C1N5)C5=CC=CC=C5)N4)C4=CC=CC=C4)N3)C3=CC=CC=C3)=N2 HGMCCUMQECCTMA-UHFFFAOYSA-N 0.000 description 1
- ONWQDMLRYHTUQV-UHFFFAOYSA-N [O-][N+](=O)c1ccc(OC(=O)N2CCC(CC2)n2ccc3ncnc(Oc4ccc(Oc5ccccc5)cc4)c23)cc1 Chemical compound [O-][N+](=O)c1ccc(OC(=O)N2CCC(CC2)n2ccc3ncnc(Oc4ccc(Oc5ccccc5)cc4)c23)cc1 ONWQDMLRYHTUQV-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- KQNKJJBFUFKYFX-UHFFFAOYSA-N acetic acid;trihydrate Chemical compound O.O.O.CC(O)=O KQNKJJBFUFKYFX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- GOOXRYWLNNXLFL-UHFFFAOYSA-H azane oxygen(2-) ruthenium(3+) ruthenium(4+) hexachloride Chemical compound N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O--].[O--].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].[Ru+3].[Ru+4] GOOXRYWLNNXLFL-UHFFFAOYSA-H 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960001482 bismuth subnitrate Drugs 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940075417 cadmium iodide Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- 239000006114 chemosensitizer Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical group C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 229940125808 covalent inhibitor Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- ICEQLCZWZXUUIJ-UHFFFAOYSA-N decan-3-ol Chemical compound CCCCCCCC(O)CC ICEQLCZWZXUUIJ-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical compound OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229940044631 ferric chloride hexahydrate Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Chemical group OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Chemical group 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000053446 human BTK Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000002429 hydrazines Chemical group 0.000 description 1
- 125000005597 hydrazone group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- FYDKNKUEBJQCCN-UHFFFAOYSA-N lanthanum(3+);trinitrate Chemical compound [La+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O FYDKNKUEBJQCCN-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000011133 lead Chemical group 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- RLJMLMKIBZAXJO-UHFFFAOYSA-N lead nitrate Chemical compound [O-][N+](=O)O[Pb]O[N+]([O-])=O RLJMLMKIBZAXJO-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical group [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- PCLIUMMFWRGXRK-UHFFFAOYSA-N methyl azetidine-1-carboxylate Chemical compound COC(=O)N1CCC1 PCLIUMMFWRGXRK-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- CVPWYDXAVJCNAG-UHFFFAOYSA-N n-(4-hydroxyphenyl)benzamide Chemical compound C1=CC(O)=CC=C1NC(=O)C1=CC=CC=C1 CVPWYDXAVJCNAG-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Chemical group 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical group C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- FYWSTUCDSVYLPV-UHFFFAOYSA-N nitrooxythallium Chemical compound [Tl+].[O-][N+]([O-])=O FYWSTUCDSVYLPV-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical group C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- QGWDKKHSDXWPET-UHFFFAOYSA-E pentabismuth;oxygen(2-);nonahydroxide;tetranitrate Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O-2].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O QGWDKKHSDXWPET-UHFFFAOYSA-E 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000004932 phenoxathinyl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- HAMAGKWXRRTWCJ-UHFFFAOYSA-N pyrido[2,3-b][1,4]oxazin-3-one Chemical compound C1=CN=C2OC(=O)C=NC2=C1 HAMAGKWXRRTWCJ-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004054 semiconductor nanocrystal Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- OUGXVMIOSSJAFK-UHFFFAOYSA-M sodium;dichloromethane;hydrogen carbonate Chemical compound [Na+].ClCCl.OC([O-])=O OUGXVMIOSSJAFK-UHFFFAOYSA-M 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- APCBTRDHCDOPNY-SSDOTTSWSA-N tert-butyl (3r)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](O)C1 APCBTRDHCDOPNY-SSDOTTSWSA-N 0.000 description 1
- ZBCXTNPVDVWHNC-UHFFFAOYSA-N tert-butyl 2-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1O ZBCXTNPVDVWHNC-UHFFFAOYSA-N 0.000 description 1
- AOEDOXQZANMVHL-UHFFFAOYSA-N tert-butyl n-(2-iodoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCI AOEDOXQZANMVHL-UHFFFAOYSA-N 0.000 description 1
- ORVXNBKOWDNMGB-UHFFFAOYSA-N tert-butyl n-(3-iodopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCI ORVXNBKOWDNMGB-UHFFFAOYSA-N 0.000 description 1
- DQARDWKWPIRJEH-UHFFFAOYSA-N tert-butyl n-(4-hydroxycyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(O)CC1 DQARDWKWPIRJEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical group [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Chemical group 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical group [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- 229910002007 uranyl nitrate Inorganic materials 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 1
- 229940041260 vanadyl sulfate Drugs 0.000 description 1
- 229910000352 vanadyl sulfate Inorganic materials 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
本出願は2013年7月31日に出願された米国仮出願第61/860,401号の利益を主張し、その内容を全体として本明細書中に取り込む。
本発明は、ブルトン型チロシンキナーゼ(BTK)の阻害剤として有用であるピリジン、ピリミジン及びピラジン化合物に関する。本発明はまた、本発明の化合物を含む医薬上許容される組成物及び該組成物の種々の障害の治療における使用方法を提供する。
プロテインキナーゼは、ヒト酵素の最大のファミリーの一つを構成し、タンパク質にリン酸基を付加することによって多くの異なるシグナル伝達プロセスを調節する(T. Hunter, Cell 1987 50:823-829)。具体的には、チロシンキナーゼは、チロシン残基のフェノール部分でタンパク質をリン酸化する。チロシンキナーゼファミリーは、細胞増殖、遊走及び分化を制御するメンバーを含む。異常なキナーゼ活性は、癌、自己免疫及び炎症性疾患を含む種々のヒト疾患に関与している。プロテインキナーゼは細胞シグナル伝達の重要な調節因子に含まれるので、小分子キナーゼ阻害剤で細胞機能を調節するターゲットを提供し、このようにして、良好な薬物ターゲットを作る。キナーゼ媒介疾患過程の処置に加えて、キナーゼ活性の選択的及び効果的な阻害剤は、細胞シグナル伝達過程の調査及び治療目的の他の細胞ターゲットの特定にも有用である。
今回、本発明の化合物及びその医薬上許容される組成物はBTKの阻害剤として有効であることを発見した。このような化合物は一般式I
1.本発明の化合物の概説
特定の態様において、本発明はBTKの阻害剤を提供する。幾つかの実施形態では、そのような化合物は本明細書に記載される式の化合物、又はその医薬上許容される塩を包含し、ここで、各変項は本明細書中に規定されそして記載されている。
本発明の化合物は上記一般に記載した化合物を包含し、本明細書中に開示されるクラス、サブクラス及び化学種によりさらに例示される。本明細書中に使用されるときに、特段の指示がないかぎり、以下の定義は適用されるであろう。本発明の目的で、化学元素は元素の周期律表CASバージョン, Handbook of Chemistry and Physics, 75th Ed.によって特定される。さらに、有機化学の一般原理は"Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999及び"March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B.及びMarch, J., John Wiley & Sons, New York: 2001に記載されており、その全内容をここに参照により取り込む。
-F、-Cl、-Br、-I、重水素、
-OH、保護ヒドロキシ、アルコキシ、オキソ、チオオキソ、
-NO2、-CN、CF3、N3、
-NH2、保護アミノ、-NHアルキル、-NHアルケニル、-NHアルキニル、-NHシクロアルキル、-NH-アリール、-NH-ヘテロアリール、-NH-複素環、-ジアルキルアミノ、-ジアリールアミノ、-ジヘテロアリールアミノ、
-O-アルキル、-O-アルケニル、-O-アルキニル、-O-シクロアルキル、-O-アリール、-O-ヘテロアリール、-O-複素環、
-C(O)-アルキル、-C(O)-アルケニル、-C(O)-アルキニル、-C(O)-カルボサイクリル、-C(O)-アリール、-C(O)-ヘテロアリール、-C(O)-ヘテロサイクリル、
-CONH2、-CONH-アルキル、-CONH-アルケニル、-CONH-アルキニル、-CONH-カルボサイクリル、-CONH-アリール、-CONH-ヘテロアリール、-CONH-ヘテロサイクリル、
-OCO2-アルキル、-OCO2-アルケニル、-OCO2-アルキニル、-OCO2-カルボサイクリル、-OCO2-アリール、-OCO2-ヘテロアリール、-OCO2-ヘテロサイクリル、-OCONH2、-OCONH-アルキル、-OCONH-アルケニル、-OCONH-アルキニル、-OCONH-カルボサイクリル、-OCONH-アリール、-OCONH-ヘテロアリール、-OCONH-ヘテロサイクリル、
-NHC(O)-アルキル、-NHC(O)-アルケニル、-NHC(O)-アルキニル、-NHC(O)-カルボサイクリル、-NHC(O)-アリール、-NHC(O)-ヘテロアリール、-NHC(O)-ヘテロサイクリル、-NHCO2-アルキル、-NHCO2-アルケニル、-NHCO2-アルキニル、-NHCO2-カルボサイクリル、-NHCO2-アリール、-NHCO2-ヘテロアリール、-NHCO2-ヘテロサイクリル、-NHC(O)NH2, -NHC(O)NH-アルキル、-NHC(O)NH-アルケニル、-NHC(O)NH-アルケニル、-NHC(O)NH-カルボサイクリル、-NHC(O)NH-アリール、-NHC(O)NH-ヘテロアリール、-NHC(O)NH-ヘテロサイクリル、NHC(S)NH2, -NHC(S)NH-アルキル、-NHC(S)NH-アルケニル、-NHC(S)NH-アルキニル、-NHC(S)NH-カルボサイクリル、-NHC(S)NH-アリール、-NHC(S)NH-ヘテロアリール、-NHC(S)NH-ヘテロサイクリル、-NHC(NH)NH2, -NHC(NH)NH-アルキル、-NHC(NH)NH-アルケニル、-NHC(NH)NH-アルケニル、-NHC(NH)NH-カルボサイクリル、-NHC(NH)NH-アリール、-NHC(NH)NH-ヘテロアリール、-NHC(NH)NH-ヘテロサイクリル、-NHC(NH)-アルキル、-NHC(NH)-アルケニル、-NHC(NH)-アルケニル、-NHC(NH)-カルボサイクリル、-NHC(NH)-アリール、-NHC(NH)-ヘテロアリール、-NHC(NH)-ヘテロサイクリル、
-C(NH)NH-アルキル、-C(NH)NH-アルケニル、-C(NH)NH-アルキニル、-C(NH)NH-カルボサイクリル、-C(NH)NH-アリール、-C(NH)NH-ヘテロアリール、-C(NH)NH-ヘテロサイクリル、
-S(O)-アルキル、-S(O)-アルケニル、-S(O)-アルキニル、-S(O)-カルボサイクリル、-S(O)-アリール、-S(O)-ヘテロアリール、-S(O)-ヘテロサイクリル-SO2NH2、-SO2NH-アルキル、-SO2NH-アルケニル、-SO2NH-アルキニル、-SO2NH-カルボサイクリル、-SO2NH-アリール、-SO2NH-ヘテロアリール、-SO2NH-ヘテロサイクリル、
-NHSO2-アルキル、-NHSO2-アルケニル、-NHSO2-アルキニル、-NHSO2-カルボサイクリル、-NHSO2-アリール、-NHSO2-ヘテロアリール、-NHSO2-ヘテロサイクリル、
-CH2NH2、CH2SO2CH3、
-モノ-、ジ-又はトリ-アルキルシリル、
-アルキル、-アルケニル、-アルキニル、-アリール、-アリールアルキル、-ヘテロアリール、-ヘテロアリールアルキル、ヘテロシクロアルキル、-シクロアルキル、-炭素環式、-複素環式、ポリアルコキシアルキル、ポリアルコキシ、-メトキシメトキシ、-メトキシエトキシ、-SH, -S-アルキル、-S-アルケニル、-S-アルキニル、-S-カルボサイクリル、-S-アリール、-S-ヘテロアリール、-S-ヘテロサイクリル又はメチルチオメチルが挙げられる。
1つの態様によると、本発明は式Iの化合物又は医薬上許容される塩を提供する。
X1 はN又はCR2であり、
X2 はN又はCR2であり、
各R2は-R、ハロゲン、-ハロアルキル、-OR、-SR、-CN、-NO2、-SO2R、-SOR、-C(O)R、-CO2R、-C(O)N(R)2、-NRC(O)R、-NRC(O)N(R)2、-NRSO2R又は-N(R)2から独立して選ばれ、
各Rは独立して、水素、C1-6 脂肪族、C3-10 アリール、3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する3〜7員複素環、又は、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する5〜6 員単環式ヘテロアリール環であり、その各々は場合により置換されていてよく、又は、
同一原子上の2つのR基はそれらが結合している原子と一緒になって、C3-10 アリール、3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する3〜7員複素環、又は、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する5〜6員単環式ヘテロアリール環を形成し、その各々は場合により置換されていてよく、
LはC1-6 脂肪族、C3-10 アリール、3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する3〜7員複素環、及び、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する5〜6員単環式ヘテロアリール環から選ばれ、その各々は場合により置換されていてよい二価基であり、又は、Lは、C1-6 脂肪族-C3-10アリール、C1-6 脂肪族-3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有するC1-6 脂肪族-3〜7 員複素環、及び、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有するC1-6脂肪族-5〜6 員単環式ヘテロアリール環から選ばれ、その各々は場合により置換されていてよい二価基であり、
Y はO、S、SO2、SO、C(O)、CO2、C(O)N(R)、-NRC(O)、-NRC(O)N(R)、-NRSO2又はN(R)であり、又は、Yは存在せず、
R1 はC1-6 脂肪族、C3-10アリール、3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する3〜7員複素環、又は、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する5〜6員単環式ヘテロアリール環であり、その各々は場合により置換されていてよく、又は、R1 はCNである)。
医薬上許容される組成物
別の実施形態によれば、本発明は、本発明の化合物又はその医薬上許容される誘導体及び医薬上許容される担体、アジュバント又はビヒクルを含む組成物を提供する。本発明の組成物における化合物の量は、生物学的サンプル又は患者において、BTK又はその変異体を測定可能に阻害するのに有効であるような量である。特定の実施形態において、本発明の組成物における化合物の量は、生物学的サンプル又は患者において、BTK又はその変異体を測定可能に阻害するのに有効であるような量である。特定の実施形態において、本発明の組成物は、そのような組成物を必要とする患者に投与するように製剤される。
特定の実施形態において、本発明は、患者又は生物学的サンプルにおいてBTK又はその変異体を阻害する方法であって、本発明に係る化合物を前記患者に投与し又は前記生物学的サンプルと接触させる工程を含む方法を提供する。
特定の態様において、本発明の化合物は検知可能な部分に結合して、プローブ化合物を形成する。1つの態様において、本発明のプローブ化合物は本明細書中に記載のとおりのいずれかの式の非可逆性プロテインキナーゼ阻害剤、検知可能な部分及び該阻害剤を該検知可能な部分に結合する結合部分を含む。
下記の実施例に記載されるとおり、特定の例示の実施形態において、化合物は以下の一般手順に従って調製される。一般方法は本発明の特定の化合物の合成を例示しているが、下記の一般方法及び当業者に知られている他の方法は本明細書中に記載のとおりのすべての化合物及びこれらの化合物の各々のサブクラス及び化学種に対して適用されうることは理解されるであろう。
ジオキサン(3.00 ml)及び水(0.30 ml)中に懸濁された4-クロロ-5H-ピロロ[3,2-d]ピリミジン (250.00 mg; 1.63 mmol)、(4-フェノキシフェニル)ボロン酸(522.64 mg: 2.44 mmol)、酢酸パラジウム (18.27 mg; 0.08 mmol)、2-ジシクロヘキシルホスフィノ-2',6'-ジメトキシビフェニル(66.83 mg; 0.16 mmol)、炭酸カリウム(674.97 mg; 0.16 mmol)を、20-mLバイアル中に入れた。反応混合物を150℃で3時間加熱された。反応混合物を室温に冷却させた。粗製混合物を、フラッシュカラムクロマトグラフィーを用いて精製した。所望の生成物を含む画分を混合し、そして減圧下に濃縮した。その後、生成物を凍結乾燥し、4-(4-フェノキシフェニル)-5H-ピロロ[3,2-d]ピリミジン (422.40 mg, 90%収率)を黄色固形分として提供した。MS: m/z = 288 [M+H]+。
DMF (6.00 ml)中に懸濁した4-クロロ-5H-ピロロ[3,2-d]ピリミジン (500.00 mg; 3.26 mmol)、炭酸セシウム(3.18 g: 9.77 mmol)及び4-フェノキシフェノール (909.40 mg; 4.88 mmol)を20-mLバイアルに入れた。反応混合物を160℃にて3時間加熱した。反応混合物を室温に冷却した。混合物を、フラッシュクロマトグラフィーを用いて精製した。所望の生成物を含む画分を混合し、そして減圧下に濃縮した。その後、生成物を一晩凍結乾燥し、4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン (611.4 mg, 62% 収率)を黄色固形分として提供した。MS: m/z = 288 [M+H]+
THF (4.00 ml)中に懸濁された4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン (200.00 mg; 0.66 mmol.)、tert-ブチル3-ヒドロキシアゼチジン-1-カルボキシレート (456.85 mg; 2.64 mmol)、トリフェニルホスフィン (1.04 g; 3.96 mmol)及びジイソプロピルアゾジカルボキシレート (800.00 mg; 3.96 mmol)を20-mLバイアル中に入れた。反応混合物を40℃で一晩加熱した。反応混合物を室温に冷却した。粗製混合物を、フラッシュカラムクロマトグラフィーを用いて精製した。所望の生成物を含む画分を混合し、そして減圧下に濃縮した。その後、混合物を分取HPLCを用いて精製した。所望の生成物を含む画分を混合し、そして一晩凍結乾燥し、tert-ブチル 3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-カルボキシレート (TFA塩、188.00 mg, 50%収率)を黄色固形分として提供した。MS: m/z = 459 [M+H]+。
DMF (8.00 ml)中に懸濁された4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン(600.00 mg; 1.98 mmol)、tert-ブチル3-ブロモアゼチジン-1-カルボキシレート (934.10 mg, 3.96 mmol)及びナトリウムtert-ブトキシド (760.42 mg, 7.91 mmol)を20-mLバイアル中に入れた。反応混合物を100℃に2日間加熱した。反応混合物を、フラッシュカラムクロマトグラフィーを用いて精製した。所望の生成物を含む画分を混合し、そして減圧下に濃縮した。その後、生成物を一晩凍結乾燥し、tert-ブチル 3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-カルボキシレート (918.00 mg, 100%収率)を黄色粘性液体として提供した。MS: m/z = 459 [M+H]+。
メタノール(5.00 ml)中に溶解したtert-ブチル 3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-カルボキシレート (910.00 mg; 1.98 mmol)を20-mLバイアル中に入れた。塩化水素(Et2O中の2.0 M溶液)(4.96 ml)を混合物に添加した。反応混合物を室温にて一晩撹拌した。反応混合物を減圧下に濃縮し、次いで、一晩凍結解凍し、5-(アゼチジン-3-イル)-4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジンを黄色固形分粗製物として提供した。MS: m/z = 359 [M+H]+。
THF (2.00 ml)及び水(0.20 ml)中に懸濁された5-(アゼチジン-3-イル)-4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン (15.00 mg; 0.04 mmol)、重炭酸ナトリウム(10.55 mg; 0.13 mmol)を20-mLバイアル中に添加した。塩化アクリロイル (0.01 ml; 0.06 mmol)を添加した。反応混合物を室温にて一晩撹拌した。粗製混合物を、フラッシュカラムクロマトグラフィーを用いて精製した。所望の生成物を含む画分を混合し、そして減圧下に濃縮した。その後、材料を、分取HPLCを用いて精製した。所望の生成物を含む画分を混合し、そして一晩凍結乾燥し、1-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オン(TFA塩、12.00 mg, 55 %収率)を白色固形分として提供した。HPLC: 85 %, RT= 3.749 min. MS: m/z = 413 [M+H]+, RT= 2.553 min. 1H-NMR (DMSO-D6) δ 8.38 (s, 1H), 8.20 (d, 1H), 7.42 (t, 2H), 7.34 (d, 2H), 7.15 (t, 1H), 7.09 (d, 2H), 7.05 (d, 2H), 6.74 (d, 1H), 6.32 (dd, 1H), 6.06 (d, 1H), 5.79 (m, 1H), 5.65(d, 1H), 4.78 (t, 1H), 4.08 (m, 1H), 4.50-4.40 (m, 2H)。
ジオキサン (3.00 ml)中に懸濁した (E)-4-(ジメチルアミノ)ブト-2-エン酸(78.50 mg; 0.61 mmol)及びビス(2-オキソ-3-オキサゾリジニル)ホスフィン酸クロリド(232.09 mg; 0.91 mmol)及びN,N-ジイソプロピルエチルアミン(0.21 ml; 1.22 mmol)を20-mLバイアル中に添加した。反応混合物を室温にて1時間撹拌した。5-(アゼチジン-3-イル)-4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン (120.00 mg; 0.30 mmol)を、その後、添加した。反応混合物を室温にて一晩撹拌した。粗製混合物を、フラッシュカラムクロマトグラフィーを用いて精製した。所望の生成物を含む画分を混合し、そして減圧下に濃縮した。その後、残留物を分取HPLCを用いて精製した。所望の生成物を含む画分を混合し、そして一晩凍結乾燥し、(E)-4-(ジメチルアミノ)-1-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)ブト-2-エン-1-オン(69.00 mg, 48%収率)を白色固体として提供した。HPLC: 95%, RT= 2.879 min. MS: m/z = 470 [M+H]+, RT= 2.016 min. 1H-NMR (DMSO-D6) δ 8.37 (s, 1H), 8.18 (d, 1H), 7.43 (t, 2H), 7.34 (d, 2H), 7.19-7.04 (m, 5H), 6.74 (d, 1H), 6.54 (三重項の二重項, 1H), 6.11 (d, 1H), 5.78 (m, 1H), 4.79-4.66 (m, 2H), 4.49-4.38 (m, 2H), 2.98 (d, 2H), 2.12 (s, 6H)。
DCM (3 mL)中に懸濁した5-(アゼチジン-3-イル)-4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン (70.00 mg, 0.18 mmol)、メタクリル酸 (30.52 mg, 0.35 mmol)、2,4,6-トリプロピル-1,3,5,2,4,6-トリオキサトリホスフィナン2,4,6-トリオキシド(338.44 mg, 0.53 mmol)、N,N-ジイソプロピルエチルアミン(0.09 ml, 0.53mmol)を20mLバイアル中に添加した。混合物を室温にて3時間撹拌した。粗製混合物を、フラッシュカラムクロマトグラフィーを用いて精製した。所望の生成物を含む画分を混合し、そして減圧下に濃縮した。その後、材料を分取HPLCを用いて精製した。所望の生成物を含む画分を混合し、そして一晩凍結乾燥し、2-メチル-1-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オン (20.00 mg, 26%収率)を白色固形として提供した。HPLC: 93%, RT= 3.838 min. MS: m/z = 427 [M+H]+, RT= 2.732 min.
アセトニトリル (3.00 ml)中に懸濁した-クロロ-5H-ピロロ[3,2-d]ピリミジン (250.00 mg; 1.63 mmol)及び4-フェノキシアニリン(452.29 mg: 2.44 mmol)を20-mLバイアル中に入れた。反応混合物を100℃にて一晩加熱した。濁った反応混合物を室温に冷却した。固形分をろ過しそしてアセトニトリルで洗浄した。固形分を真空下に乾燥し、N-(4-フェノキシフェニル)-5H-ピロロ[3,2-d]ピリミジン-4-アミン (580.00 mg, 100%収率)を黄色固形分として提供した。MS: m/z = 303 [M+H]+。
方法A、C、E及びFに記載される手順と類似の手順を用いて、1-(4-((4-(4-フェノキシフェニル)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピペリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、(4-フェノキシフェニル)ボロン酸、tert-ブチル4-(ヒドロキシメチル)ピペリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 96 %. MS: m/z = 439 [M+H]+。 1H-NMR (DMSO-D6) δ 8.91 (s, 1H), 8.00 (d, 1H), 7.70 (d, 2H), 7.48 (t, 2H), 7.25-7.19 (m, 3H), 7.11 (d, 1H), 6.77-6.69 (m, 2H), 6.04 (d, 1H), 5.62 (d, 1H), 4.25 (d, 1H), 3.93-3.87 (m, 3H), 2.68 (m, 1H), 2.30 (m, 1H), 1.34 (m, 1H), 0.92-0.75 (m, 4H)。
方法A、C、E及びFに記載される手順と類似の手順を用いて、1-(3-((4-(4-フェノキシフェニル)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピロリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、(4-フェノキシフェニル)ボロン酸、tert-ブチル 3-(ヒドロキシメチル)ピロリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 96 %. MS: m/z = 425 [M+H]+
方法A、C、E及びFに記載される手順と類似の手順を用いて、1-(3-((4-(4-フェノキシフェニル)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピペリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、(4-フェノキシフェニル)ボロン酸、tert-ブチル 3-(ヒドロキシメチル)ピペリジン-1-カルボキシレート及び塩化アクリロイルを調製した。HPLC: 94 %。 MS: m/z = 439 [M+H]+。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(4-((4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピペリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル4-(ヒドロキシメチル)ピペリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 99 %。MS: m/z = 455 [M+H]+。1H-NMR (DMSO-D6) δ 8.40 (s, 1H), 7.89 (d, 1H), 7.44 (t, 2H), 7.36 (d, 2H), 7.22-7.07 (m, 5H), 6.78 (dd, 1H), 6.67 (d, 1H), 6.07 (d, 1H), 5.64 (d, 1H), 4.43-4.36 (m, 3H), 4.05 (d, 1H), 3.00 (t, 1H), 2.59 (t, 1H), 2.21 (m, 1H), 1.59-1.47 (m, 2H), 1.26-1.09 (m, 2H)。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(3-((4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピロリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル3-(ヒドロキシメチル)ピロリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 94 %。MS: m/z = 441 [M+H]+。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(3-((4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピペリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル3-(ヒドロキシメチル)ピペリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 86 %。 MS: m/z = 455 [M+H]+。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(4-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)ピペリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル4-ヒドロキシピペリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 98 %。MS: m/z = 441 [M+H]+。
方法A、C、E及びFに記載される手順と類似の手順を用いて、1-(4-((4-(3-フェノキシフェニル)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピペリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、(3-フェノキシフェニル)ボロン酸、tert-ブチル 4-(ヒドロキシメチル)ピペリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 98 %。MS: m/z = 439 [M+H]+。 1H-NMR (DMSO-D6) δ 8.92 (s, 1H), 8.03 (d, 1H), 7.61 (t, 1H), 7.47-7.42 (m, 3H), 7.27-7.24 (m, 2H), 7.20 (t, 1H), 7.09 (d, 2H), 6.78 (d, 1H), 6.72 (dd, 1H), 6.05 (d, 1H), 5.63 (d, 1H), 4.26 (d, 1H), 3.95-3.85 (m, 3H), 2.70 (m, 1H), 2.30 (m, 1H), 1.40 (m, 1H), 0.94-0.75 (m, 4H)。
方法A、C、E及びFに記載される手順と類似の手順を用いて、1-(3-((4-(3-フェノキシフェニル)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピロリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、(3-フェノキシフェニル)ボロン酸、tert-ブチル3-(ヒドロキシメチル)ピロリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 90 %。MS: m/z = 425 [M+H]+。
方法A、C、E及びFに記載される手順と類似の手順を用いて、1-(4-(4-(3-フェノキシフェニル)-5H-ピロロ[3,2-d]ピリミジン-5-イル)ピペリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、(3-フェノキシフェニル)ボロン酸、tert-ブチル4-ヒドロキシピペリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 100 %。 MS: m/z = 425 [M+H]+。
方法A、C、E及びFに記載される手順と類似の手順を用いて、1-(3-((4-(3-フェノキシフェニル)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピペリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、(3-フェノキシフェニル)ボロン酸、tert-ブチル3-(ヒドロキシメチル)ピペリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 98 %。MS: m/z = 439 [M+H]+。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(6-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)-2-アザスピロ[3.3]ヘプタン-2-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル6-ヒドロキシ-2-アザスピロ[3.3]ヘプタン-2-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 92 %。 MS: m/z = 453 [M+H]+。 1H-NMR (DMSO-D6) δ 8.35 (s, 1H), 8.09 (d, 1H), 7.44 (t, 2H), 7.36 (d, 2H), 7.19-7.07 (m, 5H), 6.69 (d, 1H), 6.33-6.23 (m, 1H), 6.08 (d, 1H), 5.66 (d, 1H), 5.27 (m, 1H), 4.38 (s, 1H), 4.22 (s, 1H), 4.08 (s, 1H), 3.92 (s, 1H), 2.90-2.77 (m, 4H)。
方法B、C、E及びFに記載される手順と類似の手順を用いて、(S)-1-(2-((4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、(S)-tert-ブチル2-(ヒドロキシメチル)アゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 80 %。MS: m/z = 427 [M+H]+。
方法B、C、E及びFに記載される手順と類似の手順を用いて、(R)-1-(2-((4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、(R)-tert-ブチル 2-(ヒドロキシメチル)アゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 84 %。MS: m/z = 427 [M+H]+。
方法B、C、E及びGに記載される手順と類似の手順を用いて、(E)-4-(ジメチルアミノ)-1-(4-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)ピペリジン-1-イル)ブト-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル4-ヒドロキシピペリジン-1-カルボキシレート及び (E)-4-(ジメチルアミノ)ブト-2-エン酸から調製した。HPLC: 99 %。 MS: m/z = 498 [M+H]+。
方法B、C、E及びFに記載される手順と類似の手順を用いて、N-(シス-3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)シクロブチル)アクリルアミドを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル(トランス-3-ヒドロキシシクロブチル)カルバメート及び塩化アクリロイルから調製した。HPLC: 99 %。MS: m/z = 427 [M+H]+。
方法B、C、E及びGに記載される手順と類似の手順を用いて、(E)-4-(ジメチルアミノ)-1-(3-((4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)ピペリジン-1-イル)ブト-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル3-(ヒドロキシメチル)ピペリジン-1-カルボキシレート及び(E)-4-(ジメチルアミノ)ブト-2-エン酸から調製した。HPLC: 100 %。 MS: m/z = 512 [M+H]+。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(3-((4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)メチル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル 3-(ヒドロキシメチル)アゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 74 %。MS: m/z = 427 [M+H]+。
方法B、C、E及びGに記載される手順と類似の手順を用いて、N-(トランス-3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)シクロブチル)アクリルアミドを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル(シス-3-ヒドロキシシクロブチル)カルバメート及び塩化アクリロイルから調製した。HPLC: 97 %。MS: m/z = 427 [M+H]+。 1H-NMR (DMSO-D6) δ 8.66 (s, 1H), 8.36 (s, 1H), 8.21 (d, 1H), 7.43 (t, 2H), 7.35 (d, 2H), 7.19-7.06 (m, 5H), 6.72 (d, 1H), 6.23 (dd, 1H), 6.10 (d, 1H), 5.62-5.56 (m, 2H), 4.39 (m, 1H), 2.97-2.90 (m, 2H), 2.64-2.56 (m, 2H)。
方法B、C、E及びFに記載される手順と類似の手順を用いて、N-(トランス-4-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)シクロヘキシル)アクリルアミドを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル(シス-4-ヒドロキシシクロヘキシル)カルバメート及び塩化アクリロイルから調製した。HPLC: 99 %。MS: m/z = 455 [M+H]+。 1H-NMR (DMSO-D6) δ 8.35 (s, 1H), 8.04-7.99 (m, 2H), 7.43 (t, 2H), 7.37 (d, 2H), 7.19-7.06 (m, 5H), 6.68 (d, 1H), 6.21-6.06 (m, 2H), 5.58 (d, 1H), 4.83 (m, 1H), 3.77 (m, 1H), 2.22-2.14 (m, 2H), 2.05-1.96 (m, 4H), 1.50-1.38 (m, 2H)。
方法B、C、E及びFに記載される手順と類似の手順を用いて、(R)-1-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)ピロリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、(S)-tert-ブチル3-ヒドロキシピロリジン-1-カルボキシレート及び塩化アクリロイルから調製した。 HPLC: 100 %。 MS: m/z = 427 [M+H]+。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(3-(4-(4-(4-フルオロフェノキシ)フェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-(4-フルオロフェノキシ)フェノール、tert-ブチル3-ヒドロキシアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 98 %。 MS: m/z = 431 [M+H]+。 1H-NMR (DMSO-D6) δ 8.37 (s, 1H), 8.19 (d, 1H), 7.35-7.24 (m, 4H), 7.14-7.06 (m, 4H), 6.74 (d, 1H), 6.32 (dd, 1H), 6.07 (d, 1H), 5.79 (m, 1H), 5.66 (d, 1H), 4.78 (t, 1H), 4.69 (m, 1H), 4.51-4.41 (m, 2H)。
方法B, C, E及びFに記載される手順と類似の手順を用いて、(S)-1-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)ピロリジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、(R)-tert-ブチル3-ヒドロキシピロリジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 100 %。MS: m/z = 427 [M+H]+。
方法A、C、E及びFに記載される手順と類似の手順を用いて、1-(3-(6-(4-フェノキシフェニル)-1H-ピラゾロ[3,4-b]ピラジン-1-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、6-クロロ-1H-ピラゾロ[3,4-b]ピラジン、(4-フェノキシフェニル)ボロン酸、tert-ブチル3-ヒドロキシアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 100 %。MS: m/z = 398 [M+H]+。 1H-NMR (DMSO-D6) δ 9.32 (s, 1H), 8.60 (s, 1H), 8.32 (d, 2H), 7.47 (t, 2H), 7.26-7.12 (m, 5H), 6.43 (dd, 1H), 6.19 (d, 1H), 5.91 (m, 1H), 5.74 (d, 1H), 4.86 (t, 1H), 4.73 (m, 1H), 4.55 (t, 1H), 4.46 (m, 1H)。
方法I、D、E及びFに記載される手順と類似の手順を用いて、1-(3-(4-((4-フェノキシフェニル)アミノ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシアニリン、tert-ブチル3-ヨードアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 87 %。 MS: m/z = 412 [M+H]+。
方法B、C、E及びGに記載される手順と類似の手順を用いて、(E)-4-(ジメチルアミノ)-N-(トランス-3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)シクロブチル)ブト-2-エンアミドを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル (シス-3-ヒドロキシシクロブチル)カルバメート及び(E)-4-(ジメチルアミノ)ブト-2-エン酸から調製した。HPLC: 100 %。MS: m/z = 484 [M+H]+。 1H-NMR (DMSO-D6) δ 8.57 (d, 1H), 8.33 (s, 1H), 8.18 (d, 1H), 7.43 (t, 2H), 7.34 (d, 2H), 7.19-7.06 (m, 5H), 6.70 (d, 1H), 6.57 (三重項の二重項, 1H), 6.06 (d, 1H), 5.57 (五重項, 1H), 4.37 (m, 1H), 3.08-2.99 (m, 2H), 2.97-2.87 (m, 2H), 2.63-2.55 (m. 2H), 2.17 (s, 6H)。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(3-(4-(4-ベンジルフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-ベンジルフェノール、tert-ブチル3-ヒドロキシアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 100 %。 MS: m/z = 411 [M+H]+。 1H-NMR (DMSO-D6) δ 8.32 (s, 1H), 8.19 (d, 1H), 7.33-7.28 (m, 6H), 7.23-7.20 (m, 3H), 6.73 (d, 1H), 6.31 (dd, 1H), 6.05 (d, 1H), 5.78 (m, 1H), 5.63 (d, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 4.50-4.38 (m, 2H), 3.99 (s, 2H)。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(3-(4-(4-(ベンジルオキシ)フェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-(ベンジルオキシ)フェノール、tert-ブチル3-ヒドロキシアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 100 %。MS: m/z = 427 [M+H]+。 1H-NMR (DMSO-d6) δ 8.33 (s, 1H), 8.18 (d, 1H), 7.51-7.32 (m, 5H), 7.24 (d, 2H), 7.08 (d, 2H), 6.73 (d, 1H), 6.32 (dd, 1H), 6.06 (d, 1H), 5.79 (m, 1H), 5.65 (d, 1H), 5.15 (s, 2H), 4.78 (t, 1H), 4.68 (m, 1H), 4.52-4.38 (m, 2H)。
方法A、D、E及びFに記載される手順と類似の手順を用いて、1-(3-(3-(4-フェノキシフェニル)-5H-ピロロ[2,3-b]ピラジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、3-ブロモ-5H-ピロロ[2,3-b]ピラジン、(4-フェノキシフェニル)ボロン酸、tert-ブチル3-ヨードアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 100 %。MS: m/z = 397 [M+H]+。1H-NMR (DMSO-d6) δ 9.08 (s, 1H), 8.22-8.16 (m, 3H), 7.45 (t, 2H), 7.21 (t, 1H), 7.13-7.07 (m, 4H), 6.76 (d, 1H), 6.43 (dd, 1H), 6.19 (d, 1H), 5.76-5.63 (m, 2H), 4.81 (d, 2H), 4.51 (d, 2H)。
方法B、D、E及びFに記載される手順と類似の手順を用いて、N-(4-((5-(1-アクリロイルアゼチジン-3-イル)-5H-ピロロ[3,2-d]ピリミジン-4-イル)オキシ)フェニル)ベンズアミドを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、N-(4-ヒドロキシフェニル)ベンズアミド、tert-ブチル3-ヨードアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 94 %。MS: m/z = 440 [M+H]+。 1H-NMR (DMSO-d6) δ 10.34 (s, 1H), 8.36 (s, 1H), 8.20 (d, 1H), 7.99 (d, 2H), 7.85 (d, 2H), 7.65-7.52 (m, 3H), 7.31 (d, 2H), 6.75 (d, 1H), 6.34 (dd, 1H), 6.08 (d, 1H), 5.81 (m, 1H), 5.67 (d, 1H), 4.85-4.66 (m, 2H), 4.55-4.40 (m, 2H)。
方法B、C、E及びFに記載される手順と類似の手順を用いて、1-(3-(4-(4-(フェニルアミノ)フェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-(フェニルアミノ)フェノール、tert-ブチル3-ヒドロキシアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 100 %。 MS: m/z = 412 [M+H]+。 1H-NMR (DMSO-d6) δ 8.35 (s, 1H), 8.20-8.16 (m, 2H), 7.28-7.05 (m, 8H), 6.83 (t, 1H), 6.73 (d, 1H), 6.34 (dd, 1H), 6.08 (d, 1H), 5.80 (m, 1H), 5.67 (d, 1H), 4.79 (t, 1H), 4.69 (m, 1H), 4.54-4.38 (m, 2H)。
方法A、D、E及びFに記載される手順と類似の手順を用いて、1-(3-(6-(4-フェノキシフェニル)-1H-ピロロ[3,2-b]ピリジン-1-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、6-クロロ-1H-ピロロ[3,2-b]ピリジン、(4-フェノキシフェニル)ボロン酸、tert-ブチル3-ヨードアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。 HPLC: 98 %。 MS: m/z = 396 [M+H]+。 1H-NMR (DMSO-d6) δ 8.69 (s, 1H), 8.18 (s, 1H), 8.11 (d, 1H), 7.79 (d, 2H), 7.43 (t, 3H), 7.21-7.05 (m, 5H), 6.72 (d, 1H), 6.42 (dd, 1H), 6.19 (d, 1H), 5.78-5.62 (m, 2H), 4.81 (t, 1H), 4.66-4.49 (m, 2H), 4.32 (m, 1H)。
方法B、C、E、G、E及びGに記載される手順と類似の手順を用いて、(E)-5,5-ジフルオロ-1,3-ジメチル-7-(3-オキソ-3-((2-(4-(4-オキソ-4-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)ブト-2-エン-1-イル)ピペラジン-1-イル)エチル)アミノ)プロピル)-5H-ジピロロ[1,2-c:2',1'-f][1,3,2]ジアザボリニン-4-イウム-5-ウイドを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル3-ヒドロキシアゼチジン-1-カルボキシレート、(E)-4-(4-(2-((tert-ブトキシカルボニル)アミノ)エチル)ピペラジン-1-イル)ブト-2-エン酸及び7-(2-カルボキシエチル)-5,5-ジフルオロ-1,3-ジメチル-5H-ジピロロ[1,2-c:2',1'-f][1,3,2]ジアザボリニン-4-イウム-5-ウイドから調製した。HPLC: 95 %。 MS: m/z = 829 [M+H]+。
方法B、D、E、G、E及びHに記載される手順と類似の手順を用いて、(E)-6-((7-ニトロベンゾ[c][1,2,5]オキサジアゾール-4-イル)アミノ)-N-(2-(4-(4-オキソ-4-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)ブト-2-エン-1-イル)ピペラジン-1-イル)エチル)ヘキサンアミドを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル3-ヨードアゼチジン-1-カルボキシレート、(E)-4-(4-(2-((tert-ブトキシカルボニル)アミノ)エチル)ピペラジン-1-イル)ブト-2-エン酸及び6-((7-ニトロベンゾ[c][1,2,5]オキサジアゾール-4-イル)アミノ)ヘキサン酸から調製した。HPLC: 95 %。MS: m/z = 830 [M+H]+。
方法B、D、E及びFに記載される手順と類似の手順を用いて、3-メチル-1-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)ブト-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル3-ブロモアゼチジン-1-カルボキシレート及び3-メチルブト-2-エノイルクロリドから調製した。HPLC: 100 %。 MS: m/z = 441 [M+H]+。 1H-NMR (DMSO-d6) δ 8.36 (s, 1H), 8.16 (d, 1H), 7.43 (t, 2H), 7.33 (d, 2H), 7.20-7.04 (m, 5H), 6.73 (d, 1H), 5.78-5.67 (m, 2H), 4.70-4.55 (m, 2H), 4.45-4.31 (m, 2H), 2.00 (s, 3H), 1.81 (s, 3H)。
方法B、D、E及びHに記載される手順と類似の手順を用いて、(E)-1-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)ブト-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル3-ブロモアゼチジン-1-カルボキシレート及び(E)-ブト-2-エン酸から調製した。. HPLC: 98 %。MS: m/z = 427 [M+H]+。 1H-NMR (DMSO-d6) δ 8.37 (s, 1H), 8.18 (d, 1H), 7.43 (t, 2H), 7.34 (d, 2H), 7.17 (t, 1H), 7.12-7.04 (m, 4H), 6.74 (d, 1H), 6.61 (m, 1H), 6.02 (d, 1H), 5.78 (m, 1H), 4.78-4.61 (m, 2H), 4.50-4.34 (m, 2H), 1.81 (d, 3H)。
方法B、D、E及びHに記載される手順と類似の手順を用いて、N-(2-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)エチル)アクリルアミドを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル(2-ヨードエチル)カルバメート及びアクリル酸から調製した。HPLC: 99 %。 MS: m/z = 401 [M+H]+。 1H-NMR (DMSO-d6) δ 8.32 (s, 1H), 8.19 (t, 1H), 7.74 (d, 1H), 7.43 (t, 2H), 7.34 (d, 2H), 7.20-7.04 (m, 5H), 6.62 (d, 1H), 6.13 (dd, 1H), 6.02 (d, 1H), 5.56 (d, 1H), 4.54 (t, 2H), 3.65 (q, 2H)。
方法B、D、E及びHに記載される手順と類似の手順を用いて、N-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)プロピル)アクリルアミドを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、tert-ブチル(3-ヨードプロピル)カルバメート、アクリル酸から調製した。HPLC: 97 %。 MS: m/z = 415 [M+H]+。 1H-NMR (DMSO-d6) δ 8.32 (s, 1H), 8.14 (t, 1H), 7.89 (d, 1H), 7.43 (t, 2H), 7.34 (d, 2H), 7.21-7.04 (m, 5H), 6.63 (d, 1H), 6.19-6.00 (m, 2H), 5.54 (d, 1H), 4.48 (t, 2H), 3.20-3.09 (m, 2H), 2.05 (五重項, 2H)。
方法B、D、E及びHに記載される手順と類似の手順を用いて、1-(3-(4-((1-ベンジル-1H-ピラゾール-4-イル)オキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、4-クロロ-5H-ピロロ[3,2-d]ピリミジン、1-ベンジル-1H-ピラゾール-4-オール、tert-ブチル3-ブロモアゼチジン-1-カルボキシレート、アクリル酸から調製した。HPLC: 88 %。MS: m/z = 401 [M+H]+。
方法A、D、E及びHに記載される手順と類似の手順を用いて、(E)-4-(ジメチルアミノ)-1-(3-(6-(4-フェノキシフェニル)-1H-ピロロ[3,2-b]ピリジン-1-イル)アゼチジン-1-イル)ブト-2-エン-1-オンを、6-クロロ-1H-ピロロ[3,2-b]ピリジン、(4-フェノキシフェニル)ボロン酸、tert-ブチル3-ヨードアゼチジン-1-カルボキシレート及び(E)-4-(ジメチルアミノ)ブト-2-エン酸から調製した。HPLC: 98 %。 MS: m/z = 453 [M+H]+。 1H-NMR (DMSO-d6) δ 8.69 (s, 1H), 8.16 (s, 1H), 8.10 (d, 1H), 7.78 (五重項, 1H), 4.79 (t, 1H), 4.64-4.47 (m, 2H), 4.29 (m, 1H), 3.19 (d, 2H), 2.25 (s, 6H)。
方法A、D、E及びHに記載される手順と類似の手順を用いて、(E)-4-(ジメチルアミノ)-1-(3-(3-(4-フェノキシフェニル)-5H-ピロロ[2,3-b]ピラジン-5-イル)アゼチジン-1-イル)ブト-2-エン-1-オンを、3-ブロモ-5H-ピロロ[2,3-b]ピラジン、(4-フェノキシフェニル)ボロン酸、tert-ブチル3-ヨードアゼチジン-1-カルボキシレート及び(E)-4-(ジメチルアミノ)ブト-2-エン酸から調製した。HPLC: 95 %。 MS: m/z = 454 [M+H]+。 1H-NMR (DMSO-d6) δ 9.07 (s, 1H), 8.23-8.13 (m, 3H), 7.45 (t, 2H), 7.21 (t, 1H), 7.10 (t, 4H), 6.78-6.62 (m, 2H), 6.23 (d, 1H), 5.64 (五重項, 1H), 4.79 (d, 2H), 4.48 (d, 2H), 3.08 (d, 2H), 2.16 (s, 6H)。
方法B、C、E及びHに記載される手順と類似の手順を用いて、(S,E)-4-(ジメチルアミノ)-1-(3-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)ピロリジン-1-イル)ブト-2-エン-1-オンを4-クロロ-5H-ピロロ[3,2-d]ピリミジン、4-フェノキシフェノール、(R)-tert-ブチル3-ヒドロキシピロリジン-1-カルボキシレート及び(E)-4-(ジメチルアミノ)ブト-2-エン酸から調製した。HPLC: 100 %。 MS: m/z = 484 [M+H]+。 1H-NMR (DMSO-d6) δ 10.20 (s, 1H), 8.20 (s, 1H), 8.00 (s, 1H), 7.75-7.29 (m, 8H), 6.93-6.58 (m, 3H), 6.42 (dd, 1H), 6.25 (d, 1H), 5.77 (d, 1H), 5.49 (s, 2H)。
方法A、D、E及びFに記載される手順と類似の手順を用いて、1-(3-(3-(1-ベンジル-1H-ピラゾール-4-イル)-5H-ピロロ[2,3-b]ピラジン-5-イル)アゼチジン-1-イル)プロプ-2-エン-1-オンを、3-ブロモ-5H-ピロロ[2,3-b]ピラジン、1-ベンジル-4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)-1H-ピラゾール、tert-ブチル3-ヨードアゼチジン-1-カルボキシレート及び塩化アクリロイルから調製した。HPLC: 98 %。 MS: m/z = 385 [M+H]+。 1H-NMR (DMSO-d6) δ 8.83 (s, 1H), 8.48 (s, 1H), 8.13 (s, 1H), 8.08 (d, 1H), 7.40-7.29 (m, 5H), 6.70 (d, 1H), 6.42 (dd, 1H), 6.20 (d, 1H), 5.72 (d, 1H), 5.61 (五重項, 1H), 5.40 (s, 2H), 4.81-4.70 (m, 2H), 4.49 (d, 2H)。
7-クロロ-1H-ピラゾロ[4,3-d]ピリミジン (1.00 g; 6.47 mmol; 1.00 eq.)、4-フェノキシ-フェノール (1807.17 mg; 9.71 mmol; 1.50 eq.)、炭酸セシウム(4216.18 mg; 12.94 mmol; 2.00 eq.)を含むマイクロ波バイアル中において、DMF (15.00 ml; 194.54 mmol; 30.07 eq.)を添加した。混合物を50℃で16時間撹拌し、その後、それを濃縮し、 そして50 g KPNHカラム(勾配:EOAc/ヘキサン中65〜100% EtOAc)で精製し、所望の生成物を黄色固形分として提供した( 830.7mg, 42%)。 1H NMR (CD3OD) δ 8.49 (s, 1H), 8.27 (s, 1H), 7.27-7.46 (m, 4H), 7.04-7.23 (m, 5H)。 HPLC: 98%。 MS: m/z = 305 [M+H]+。
7-(4-フェノキシ-フェノキシ)-1H-ピラゾロ[4,3-d]ピリミジン (20.00 mg; 0.07 mmol; 1.00 eq.)、トリフェニルホスフィン (51.72 mg; 0.20 mmol; 3.00 eq.)及び4-ヒドロキシ-ピペリジン-1-カルボン酸tert-ブチルエステル(26.46 mg; 0.13 mmol; 2.00 eq.)を含む10 mL マイクロ波バイアルに、THF (1.00 ml; 37.03 mmol; 563.40 eq.)を添加し、次いで、ジイソプロピル (E)-ジアゼン-1,2-ジカルボキシレート (0.04 ml; 0.20 mmol; 3.00 eq.)を添加した。溶液を室温にて1時間撹拌し、その後、それを濃縮し、精製せずに次の工程に運んだ。
メタノール(5.00 ml)中の4-[7-(4-フェノキシ-フェノキシ)-ピラゾロ[4,3-d]ピリミジン-1-イル]-ピペリジン-1-カルボン酸tert-ブチルエステル(1360.26 mg; 2.79 mmol; 1.00 eq.)を含む10mLマイクロ波バイアル中に、塩化水素(ジオキサン中4.0N, 3.00 ml; 13.95 mmol; 5.00 eq.)を添加した。溶液を室温にて1時間撹拌し、その後、それを濃縮し、そして精製せずに次の工程に運んだ。
7-(4-フェノキシ-フェノキシ)-1-ピペリジン-4-イル-1H-ピラゾロ[4,3-d]ピリミジンヒドロクロリド(80.00 mg; 0.19 mmol; 1.00 eq.)、アクリル酸(12.04μl; 0.19 mmol; 1.00 eq.)、エチル-ジイソプロピル-アミン (0.16 ml; 0.94 mmol; 5.00 eq.)及び1,2-ジクロロエタン (2.00 ml; 25.26 mmol; 133.86 eq.)を10 mL反応バイアルに添加した。混合物を5分間撹拌し、その後、2,4,6-トリプロピル-[1,3,5,2,4,6]トリオキサトリホスフィナン2,4,6-トリオキシド(75.00μl; 0.19 mmol; 1.00 eq.)をゆっくり添加した。得られた混合物を室温にて1時間撹拌し、その後、それを濃縮し、そして分取-HPLC (0.1% NH4OH/H2O中の50〜80 % CH3CNから溶離する)を用いて精製し、凍結解凍後に所望の生成物を白色固形分として提供した(2.8 mg, 3.2%)。 HPLC: 96%。 MS: m/z = 442[M+H]+。 1H-NMR (MeOH-d4) δ 8.31 (s, 1H), 8.13 (s, 1H), 7.25 (m, 4H), 7.0 (m, 5H), 6.76 (d, 1H), 6.12 (d, 1H), 5.64 (d, 1H), 5.25 (s, 1H), 4.61 (d, 1H), 4.23 (d, 1H), 3.28 (m, 1H), 2.99 (t, 1H), 2.19 (m, 4H)。
方法J、K、L及びMに記載される手順と類似の手順を用いて、N-((1s,3s)-3-(7-(4-フェノキシフェノキシ)-1H-ピラゾロ[4,3-d]ピリミジン-1-イル)シクロブチル)アクリルアミドを、7-クロロ-1H-ピラゾロ[4,3-d]ピリミジン、4-フェノキシフェノール、tert-ブチル ((1s,3s)-3-アミノシクロブチル)カルバメート及びアクリル酸から調製した。 HPLC: 99%。 MS: m/z = 428 [M+H]+。 1H NMR (CDCl3) δ 8.56 (s, 1H), 7.39 (s, 1H), 7.11-7.41 (m, 11H), 6.36 (d, 1H), 6.08 (m, 2H), 5.73 (m, 1H), 5.47 (m, 1H), 4.56 (m, 1H), 3.17 (m, 2H), 2.79 (m, 2H)。
方法J、K、L及びMに記載される手順と類似の手順を用いて、(E)-4-(ジメチルアミノ)-N-((1s,3s)-3-(7-(4-フェノキシフェノキシ)-1H-ピラゾロ[4,3-d]ピリミジン-1-イル)シクロブチル)ブト-2-エンアミドを、7-クロロ-1H-ピラゾロ[4,3-d]ピリミジン、4-フェノキシフェノール、tert-ブチル ((1s,3s)-3-アミノシクロブチル)カルバメート及び(E)-4-(ジメチルアミノ)ブト-2-エン酸ヒドロクロリドから調製した。HPLC: 93%。 MS: m/z = 485[M+H]+。 1H NMR (CDCl3) δ 8.56 (s, 1H), 8.37 (s, 1H), 7.11-7.41 (m, 11H), 6.40 (m, 1H), 5.48 (m, 1H), 5.02 (m, 2H), 4.47 (m, 1H), 3.86 (m, 1H), 3.17 (m, 2H), 2.94 (m, 8H)。
方法J、K、L及びMに記載される手順と類似の手順を用いて、N-((1r,3r)-3-(7-(4-フェノキシフェノキシ)-1H-ピラゾロ[4,3-d]ピリミジン-1-イル)シクロブチル)-3-(ピペリジン-1-イル)プロパンアミドを、7-クロロ-1H-ピラゾロ[4,3-d]ピリミジン、4-フェノキシフェノール、tert-ブチル ((1r,3r)-3-アミノシクロブチル)カルバメート及びアクリル酸から調製した。HPLC: 99%。 MS: m/z = 428 [M+H]+。 1H NMR (CDCl3) δ 8.54 (s, 1H), 8.36 (s, 1H), 7.11-7.41 (m, 11H), 6.33 (d, 1H), 6.15 (m, 1H), 5.92 (m, 1H), 5.72 (m, 1H), 3.27 (m, 2H), 2.80 (m, 2H)。
方法J、K、L及びMに記載される手順と類似の手順を用いて、(E)-4-(ジメチルアミノ)-N-((1r,3r)-3-(7-(4-フェノキシフェノキシ)-1H-ピラゾロ[4,3-d]ピリミジン-1-イル)シクロブチル)ブト-2-エンアミドを、7-クロロ-1H-ピラゾロ[4,3-d]ピリミジン、4-フェノキシフェノール、tert-ブチル ((1r,3r)-3-アミノシクロブチル)カルバメート及び(E)-4-(ジメチルアミノ)ブト-2-エン酸ヒドロクロリドから調製した。HPLC: 99%。MS: m/z = 485 [M+H]+。 1H NMR (CDCl3) δ 8.55 (s, 1H), 8.29 (s, 1H), 7.11-7.41 (m, 11H), 6.79 (d, 1H), 6.43 (m, 2H), 5.81 (m, 1H), 5.00 (m, 1H), 4.75(m, 1H), 3.75 (m, 2H), 3.19 (m, 2H), 2.89 (s, 6H)。
方法J、K、L及びMに記載される手順と類似の手順を用いて、(E)-4-(ジメチルアミノ)-1-(4-(7-(4-フェノキシフェノキシ)-1H-ピラゾロ[4,3-d]ピリミジン-1-イル)ピペリジン-1-イル)ブト-2-エン-1-オンを、7-クロロ-1H-ピラゾロ[4,3-d]ピリミジン、4-フェノキシフェノール、tert-ブチル 4-ヒドロキシピペリジン-1-カルボキシレート及び(E)-4-(ジメチルアミノ)ブト-2-エン酸ヒドロクロリドから調製した。HPLC: 95%。 MS: m/z = 499 [M+H]+。 1H NMR (DMSO-d6) δ 8.50 (s, 1H), 8.43 (s, 1H), 7.46 (m, 4H), 7.11 (m, 5H), 6.79 (m, 1H), 6.59 (m, 1H), 5.23 (m, 1H), 4.52 (m, 1H), 4.25 (m,1H), 2.96 (t, 1H), 2.47 (s, 6H), 2.22 (m, 2H), 2.04 (m, 2H)。
(3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]アゼチジン (700 mg, 1.95 mmol, 1.00当量)のジクロロメタン/水(3:1, 10 mL)中の溶液に、重炭酸ナトリウム(657 mg, 7.82 mmol, 4.00 当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide)(249 mg, 2.35 mmol, 1.20 当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水でクエンチし、そして3 x 20 mL ジクロロメタンで抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物を下記の条件下に分取HPLCにより精製した: XBridge Prep C18 OBD カラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 11分で40.0%〜50.0% 勾配。3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]アゼチジン-1-カルボニトリルを黄色固形分として得た(3工程で30 mg, 10%)。 HPLC: 99.0 %, RT = 1.805 min. MS: m/z = 384.3 [M+H]+。 1H-NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.25 (d, J = 3.2 Hz, 1H), 7.36-7.45 (m, 4H), 7.05-7.18 (m, 5H), 6.77 (d, J = 3.2 Hz, 1H), 5.79-5.87 (m, 1H), 4.65-4.72 (m, 4H)。
室温にて、3-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピロリジン (780 mg, 2.02 mmol, 1.00当量)のジクロロメタン/水(10:4, 14 mL)中の溶液に、重炭酸ナトリウム(679 mg, 8.08 mmol, 4.00当量)及び臭化炭窒素(carbononitridic bromide)(254 mg, 2.40 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を3 x 10 mLのジクロロメタンで抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBD カラム、 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む)、 10分で35.0%〜70.0%勾配。3-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピロリジン-1-カルボニトリルをオフホワイト色固形分として得た(230 mg, 28%)。HPLC: 97.3%, RT = 2.027 min. MS: m/z = 412.4 [M+H]+。 1H-NMR (400 MHz, DMSO-d6) δ 8.33(s, 1H),7.90(d, J=4Hz,1H), 7.45-7.35(m, 4H), 7.18-7.06(m, 5H), 6.67-6.66(d, J=4Hz,1H), 4.53-4.42(m, 2H), 3.52-3.49(m, 1H), 3.48-3.37(m, 2H), 3.35-3.18(m, 1H), 2.91-2.84(m, 1H), 1.91-1.83(m, 1H), 1.72-1.65(m, 1H)。
2-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピロリジン (382 mg, 0.99 mmol, 1.00当量)のジクロロメタン/水(3:1, 8 mL)中の溶液に、重炭酸ナトリウム(333 mg, 3.96 mmol, 4.00 当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide) (126 mg, 1.19 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水でクエンチし、3 x 20 mLのジクロロメタンで抽出した。有機相を合わせ、そして無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBD カラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 10分で40%〜65%勾配。2-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピロリジン-1-カルボニトリルを黄色固形分として得た(3工程で34 mg, 10%)。HPLC: 99.4%, RT = 2.009 min. MS: m/z = 412.2 [M+H]+。 1H-NMR (400 MHz, DMSO-d6) δ 8.33 (s, 1H), 7.88 (d, J = 3.2 Hz, 1H), 7.45-7.40 (m, 2H), 7.36-7.33 (m, 2H), 7.19-7.06 (m, 5H), 6.68 (d, J = 3.2 Hz, 1H), 4.59-4.53 (m, 1H), 4.49-4.43 (m, 1H), 4.16-4.13。
4-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピペリジン (80 mg, 0.20 mmol, 1.00当量)のジクロロメタン/水(10:4, 5 mL)中の溶液に、重炭酸ナトリウム(67 mg, 0.80 mmol, 4.00当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide) (25 mg, 0.24 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。得られた混合物を減圧下に濃縮した。粗製生成物を、分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBD カラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 10分で35.0%〜70.0% 勾配。4-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピペリジン-1-カルボニトリルを白色固形分として得た(30 mg, 35%)。 HPLC: 97.7%, RT = 2.028 min. MS: m/z = 426.1 [M+H]+。 1H-NMR (400 MHz, DMSO-d6) δ 8.32 (s, 1H) 7.85 (d, J=3.2Hz, 1H), 7.45-7.41 (m, 2H), 7.19-7.06 (m, 5H), 6.64 (s, 1H) , 4.35 (d, J=7.2Hz, 2H), 3.37-3.30 ( m, 2H), 2.96 (m, 2H), 2.10-2.05 (m, 1H), 1.46-1.37 (m, 4H)。
3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]ピロリジン (74 mg, 0.20 mmol, 1.00当量)のジクロロメタン/水(10:4, 3 mL)中の溶液に、重炭酸ナトリウム(67 mg, 0.80 mmol, 4.00当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide) (25 mg, 0.24 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を減圧下に濃縮した。粗製生成物を、分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBD カラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 10分で35.0%〜70.0%勾配。3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]ピロリジン-1-カルボニトリルを白色固形分として得た(30 mg, 38%)。HPLC: 98.9%, RT = 1.922 min. MS: m/z = 398.1 [M+H]+。1H-NMR (400 MHz, DMSO-d6) δ 8.35 ( s, 1H), 7.96 (d, J = 3.2Hz, 1H), 7.45-7.35 (m, 4H), 7.18-7.05(m, 5H), 6.70 (d, J = 3.2 Hz, 1H), 5.63 (t, J = 5.2 Hz, 1H), 3.94-3.83 (m, 2H) 3.68-3.60 ( m, 2H), 3.32-3.30 ( m, 2H)。
(3R)-3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]ピロリジン (340 mg, 0.91 mmol, 1.00当量)のジクロロメタン/水(10:4, 3 mL)中の溶液に、重炭酸ナトリウム(368 mg, 4.38 mmol, 4.80当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide) (116 mg, 1.10 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を減圧下に濃縮した。残留物を分取HPLC により下記の条件で精製した: XBridge Prep C18 OBDカラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 10分で30.0%〜65.0%勾配。3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]ピロリジン-1-カルボニトリルを白色固形分として得た(300 mg, 3工程で46%)。HPLC: 95.0%, RT = 3.061 min. MS: m/z = 398.1 [M+H]+。 1H-NMR (400 MHz, CDCl3) δ 8.60-8.40 (s, 1H), 7.60-7.45 (s, 1H), 7.40-7.30 (m, 2H), 7.20-7.00 (m, 7H), 6.90-6.75 (s, 1H), 5.85-5.60 (m, 1H), 4.10-3.95 (m, 1H), 3.90-3.75 (m, 1H), 3.75-3.55 (m, 2H), 2.70-2.50 (m, 1H), 2.50-2.30 (m, 1H)。
(3S)-3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]ピロリジン (340 mg, 0.91 mmol, 1.00当量)のジクロロメタン/水(3:1, 10 mL)中の溶液に、重炭酸ナトリウム(368 mg, 4.38 mmol, 4.80当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide) (116 mg, 1.10 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を減圧下に濃縮した。残留物を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBDカラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 10分で30.0%〜65.0%勾配。3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]ピロリジン-1-カルボニトリルを白色固形分として得た(3工程で80mg, 13%)。HPLC: 95.0%, RT = 2.835 min. MS: m/z = 398.1 [M+H]+。 1H-NMR (400 MHz, CDCl3) δ 8.65-8.55 (s, 1H), 7.75-7.55 (s, 1H), 7.45-7.30 (m, 2H), 7.25-7.00 (m, 7H), 6.95-6.80 (s, 1H), 5.85-5.70 (m, 1H), 4.10-3.98 (m, 1H), 3.90-3.80 (m, 1H), 3.80-3.55 (m, 2H), 2.70-2.55 (m, 1H), 2.55-2.30 (m, 1H)。
2-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピロリジン (382 mg, 0.99 mmol, 1.00当量)のジクロロメタン/水 (3:1, 8 mL)中に溶液に、重炭酸ナトリウム(333 mg, 3.96 mmol, 4.00当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide)(126 mg, 1.19 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水でクエンチし、そして3 x 20 mLのジクロロメタンで抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBDカラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 10分で40%〜65%勾配。2-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピペリジン-1-カルボニトリルを黄色固形分として得た(3工程で34 mg, 10%)。HPLC: 96.8 %, RT = 1.515 min. MS: m/z = 426.2 [M+H]+。1H-NMR (400 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.87 (d, J = 3.2 Hz, 1H), 7.45-7.40 (m, 2H), 7.39-7.34 (m, 2H), 7.19-7.06 (m, 5H), 6.68 (d, J = 3.2 Hz, 1H), 4.78-4.72(m, 1H), 4.61-4.55 (m, 1H), 3.76-3.73 (m, 1H), 3.45-3.40 (m, 1H), 3.13-3.08 (m, 1H), 1.72-1.70 (m, 1H), 1.61-1.54 (m, 3H), 1.48-1.41 (m, 2H)。
3-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピペリジン (380 mg, 0.99 mmol, 1.00当量)のジクロロメタン/水 (3:1, 8 mL)中の溶液に、重炭酸ナトリウム(333 mg, 3.96 mmol, 4.00当量)を添加した。これに次いで、臭化炭窒素(carbononitridic bromide) (126 mg, 1.19 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水でクエンチし、そして3 x 20 mL のジクロロメタンで抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBDカラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 12分で35%〜70%勾配。3-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]ピペリジン-1-カルボニトリルを得た(3工程で32 mg, 12%)。 HPLC: 99.2 %, RT = 2.116 min. MS: m/z = 426.2 [M+H]+。 1H-NMR (400 MHz, DMSO-d6) δ 8.33 (s, 1H), 7.85 (d, J = 3.2 Hz, 1H), 7.45-7.40 (m, 2H), 7.37-7.33 (m, 2H), 7.19-7.06 (m, 5H), 6.66 (d, J = 2.8 Hz, 1H), 4.40-4.35 (m, 2H), 3.34-3.16 (m, 2H), 3.03-2.91(m, 1H), 2.89-2.86 (m, 1H), 2.27-2.23 (m, 1H), 1.71-1.46 (m, 3H), 1.28-1.18 (m, 1H)。
3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]ピペリジン (275 mg, 0.71 mmol, 1.00当量)のジクロロメタン/水(3:1, 8 mL)中の溶液に、重炭酸ナトリウム(239 mg, 2.85 mmol, 4.00当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide) (91 mg, 0.86 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水で希釈し、3 x 20 mLのジクロロメタンで抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物(100 mg)を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBD カラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 8分で30%〜75%勾配。3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]ピペリジン-1-カルボニトリルを得た(31 mg, 3工程で15%)。HPLC: 98.9 %, RT = 2.251 min. MS: m/z = 412.1 [M+H]+。 1H-NMR (400 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.98 (d, J = 3.2 Hz, 1H), 7.45-7.35 (m, 4H), 7.18-7.06 (m, 5H), 6.70 (d, J = 3.2 Hz, 1H), 5.05-5.01 (m, 1H), 3.86-3.81 (m, 1H), 3.42-3.362 (m, 2H), 3.13-3.06 (m, 1H), 2.23-2.11 (m, 2H), 1.91-1.88 (m, 2H)。
(6-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]-2-アザスピロ[3.3]ヘプタン (382 mg, 0.96 mmol, 1.00当量)のジクロロメタン/水(3:1, 10 mL)中の溶液に、重炭酸ナトリウム (322.6 mg, 3.84 mmol, 4.00当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide)(122 mg, 1.15 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水でクエンチし、そして3 x 20 mLのジクロロメタンで抽出した。有機相を合わせ、そして無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBD カラム, 19 x 150 mm, 5 um; 水中MeCN (0.1% TFAを含む), 11分で40.0%〜50.0%勾配。6-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]-2-アザスピロ[3.3]ヘプタン-2-カルボニトリルを黄色固形分として得た(3工程で30 mg, 15%)。 HPLC: 98.2%, RT = 1.802 min. MS: m/z = 424.4 [M+H]+。 1H-NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 8.05 (d, J = 3.2 Hz, 1H), 7.41-7.45 (m, 2H), 7.32-7.34 (m, 2H), 7.14-7.18 (m, 1H), 7.06-7.12 (m, 4H), 6.67 (d, J = 3.2 Hz, 1H), 5.17-5.26 (m, 1H), 4.3 (s, 2H), 4.15 (s, 2H), 2.84-2.89 (m, 2H), 2.74-2.80 (m, 2H)。
2-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル] アゼチジン (491 mg, 1.32 mmol, 1.00当量)のジクロロメタン/水(3:1, 8 mL)中の溶液に、重炭酸ナトリウム(443.5 mg, 5.28 mmol, 4.00当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide)(168 mg, 1.59 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水でクエンチし、そして3 x 20 mLのジクロロメタンで抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBD カラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 10分で46.0%〜48.0%勾配。2-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]アゼチジン-1-カルボニトリルを得た(3工程で31 mg, 8%)。HPLC: 98.6 %, RT = 1.255 min. MS: m/z = 398.1 [M+H]+。1H-NMR (400 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.88 (d, J=3.2 Hz, 1H), 7.45-7.35 (m, 4H), 7.18-7.05 (m, 5H), 6.68 (d, J=3.2 Hz, 1H), 4.91-4.87 (m, 1H), 4.72 (d, J=6 Hz, 2H), 4.08-4.01 (m, 1H), 3.85-3.79 (m, 1H), 2.37-2.29 (m, 1H), 2.18-2.15 (m, 1H)。
室温にて、3-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]アゼチジン (510 mg, 1.37 mmol, 1.00当量)のジクロロメタン/水(3:1, 10 mL)中の溶液に、重炭酸ナトリウム(460 mg, 5.48 mmol, 4.00当量)を添加した。これに次いで、臭化炭窒素(carbononitridic bromide)(173 mg, 1.63 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水でクエンチし、そして3 x 20 mLのジクロロメタンで抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBDカラム, 19 x 150 mm, 5 um; 水中MeCN (10 mM NH4HCO3を含む), 10分で30%〜70%勾配。3-[[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]メチル]アゼチジン-1-カルボニトリルを白色固形分として得た(3工程で30 mg, 15%)。HPLC: 99.5%, RT = 1.917 min. MS: m/z = 398.3 [M+H]+。 1H-NMR (400 MHz, DMSO-d6) δ 8.33 (s, 1H), 7.91 (d, J = 4 Hz, 1H), 7.45-7.35 (m, 4H), 7.18-7.06 (m, 5H), 6.67 (d, J = 4 Hz, 1H), 4.53-4.42 (m, 2H), 3.52-3.49 (m, 1H), 3.48-3.37 (m, 2H), 3.35-3.18 (m, 1H), 2.91-2.84 (m, 1H), 1.91-1.83 (m, 1H), 1.72-1.65 (m, 1H)。
0℃にて、4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン (607.0 mg, 2.00 mmol, 1.00当量)のTHF (20 mL)中の溶液に、tert-ブチル N-[(1S,3S)-3-ヒドロキシシクロブチル]カルバメート(374.70 mg, 2.00 mmol, 1.00当量)及びPPh3 (524.89 mg, 2.00 mmol, 1.00当量)を添加した。これに次いで、DIAD (404.66 mg, 2.00 mmol, 1.00当量)を0℃にてゆっくりと添加した。得られた溶液をオイルバス中50℃にて一晩撹拌した。反応混合物を減圧下に濃縮した。ヘキサン中10〜40% EtOACの勾配で溶離して、残留物をシリカゲルカラム中で精製し、tert-ブチル N-[(1R,3R)-3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロブチル]カルバメートを無色シロップとして生成した(1.3g)。
室温にて、tert-ブチル N-[(1R,3R)-3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロブチル]カルバメート (940 mg, 1.99 mmol, 1.00当量)をTHF (15 mL)中に溶解した。これに次いで、LiAlH4 (150 mg, 3.95 mmol, 2.00当量)を1分間にわたって小分けして添加した。得られた溶液を60℃で3時間撹拌した。その後、反応を20 mLの水でクエンチした。混合物のpH値をHCl溶液(2 M)で3に調節した。その後、混合物を3 x 50 mLの酢酸エチルで抽出した。水性相のpH値を水酸化ナトリウム溶液(2 M)で10に調節して戻した。その後、水溶液を2 x 30 mLのDCM/MeOH=30:1で抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮し、(1R,3R)-N-メチル-3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロブタン-1-アミンをオレンジ色シロップとして生成した(2工程で280 mg, 36%)。
(1R,3R)-N-メチル-3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロブタン-1-アミン (250.00 mg, 0.65 mmol, 1.00当量)のジクロロメタン/水(3:1, 10 mL)中の溶液に、重炭酸ナトリウム (217.38 mg, 2.59 mmol, 4.00当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide)(82.23 mg, 0.78 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水でクエンチし、そして3 x 20 mLのジクロロメタンで抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。粗製生成物(250 mg)を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBD カラム, 19 x 150 mm, 5 um;水中MeCN (10 mM NH4HCO3を含む), 12分で25%〜75%勾配。(1R,3R)-N-シアノ-N-メチル-3-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロブタン-1-アミンを黄色固形分として得た(40 mg, 15%)。 HPLC: 99.0 %, RT = 1.948 min. MS: m/z = 412.3 [M+H]+。 1H-NMR (400 MHz, CDCl3) δ 8.51 ( s, 1H), 7.58 (d, J=3.2Hz, 1H), 7.58 (d, J=3.2Hz, 1H), 7.38 (t, J=8.0Hz, 2H), 7.28-7.21 (m, 2H), 7.17-7.09 (m, 5H), 6.75 (d, J=3.2Hz, 1H), 5.65-5.57 (m, 1H), 3.84-3.78 (m, 1H), 2.97-2.85(m, 7H)。
室温にて、1,4-ジオキサスピロ [4.5]デカン-8-オン(5.00 g, 32.01 mmol, 1.00当量)をTHF (50 mL)中に溶解した。これに次いで、LiAlH4 (1.22 g, 32.14 mmol, 1.00当量) を0℃で5分間にわたって小分けして添加した。その後、混合物を0℃で2時間撹拌した。その後、反応を10 mLの水の添加でクエンチした。この混合物のpH値をHCl溶液(2 M)で1.0に調節し、それを3 x 100 mLの酢酸エチルで抽出した。有機相を合わせ、そして2 x 50 mLのブラインで洗浄し、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮し、 1,4-ジオキサスピロ[4.5]デカン-8-オールを無色オイルとして生成した(3.2 g, 63%)。
0℃にて、4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン (607.0 mg, 2.0 mmol, 1.0当量)のTHF (25 mL)中の溶液に、1,4-ジオキサスピロ [4.5]デカン-8-オール(949.75 mg, 6.00 mmol, 3.00当量)及びPPh3 (1.57 mg, 6.00 mmol, 3.00当量)を添加した。これに次いで、テトラヒドロフラン(5 mL)中のDIAD (1.21g, 6.00 mmol, 3.00当量)を0℃にて滴下して加えた。得られた溶液を室温にて一晩撹拌した。反応混合物を減圧下に濃縮し、5-[1,4-ジオキサスピロ[4.5]デカン-8-イル]-4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジンを白色固形分として生成した(1.7g, 粗製)。
室温にて、5-[1,4-ジオキサスピロ [4.5]デカン-8-イル]-4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d] ピリミジン (1.4 g, 3.16 mmol, 1.00当量)のTHF/水(1:1, 30 mL)中の溶液に、塩化水素溶液(2 mL, 12 N)を添加した。得られた溶液を50℃にて一晩撹拌した。反応混合物を減圧下に濃縮した。残留物を10 mLのH2Oで希釈し、そのpH値を水酸化ナトリウム溶液(2 M)を用いて10に調節した。混合物を2 x 30 mLのジクロロメタンで抽出し、そして有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。ヘキサン中の5%〜30% EtOACの勾配で溶離して、残留物をシリカゲルカラムにおいて精製し、4-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロヘキサン-1-オンを白色固形分として生成した(1.5 g)。
室温にて、4-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロヘキサン-1-オン(400.00 mg, 1.00 mmol, 1.00当量)のメタノール(10 mL)中の溶液に、AcOH (30 mg, 0.50 mmol, 0.50当量)を添加し、次いで、メタンアミン (124 mg, 3.99 mmol, 4.00当量)を添加した。得られた溶液を室温にて4時間撹拌した。その後、NaBH4 (75.77 mg, 2.00 mmol, 2.00当量)を添加し、そして混合物を一晩室温にて撹拌し続けた。反応混合物を減圧下に濃縮した。残留物をシリカゲルカラムでジクロロメタン中の5%〜35%メタノールの勾配で溶離して精製し、N-メチル-4-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロヘキサン-1-アミンを白色固形分として生成した(3工程で300 mg, 36%)。
(N-メチル-4-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロヘキサン-1-アミン (290.00 mg, 0.70 mmol, 1.00当量)のジクロロメタン/水 (3:1, 8 mL)中の溶液に重炭酸ナトリウム(117.55 mg, 1.40 mmol, 2.00当量)を室温にて添加した。これに次いで、臭化炭窒素(carbononitridic bromide) (88.93 mg, 0.84 mmol, 1.20当量)を添加した。得られた溶液を室温にて一晩撹拌した。反応混合物を10 mLの水でクエンチし、そして3 x 20 mLのジクロロメタンで抽出した。有機相を合わせ、無水硫酸ナトリウム上で乾燥し、そして減圧下に濃縮した。残留物を分取HPLCにより下記の条件で精製した: XBridge Prep C18 OBDカラム, 19 x 150 mm, 5 um; 水中MeCN (0.05% TFAを含む), 10分で30%〜70%勾配。粗製生成物(120 mg)を得て、それをキラル-分取HPLCにより下記の条件で再び精製した: Phenomenex Lux 5u Cellulose-4AXIA 充填カラム, 250 x 21.2 mm, 5 um; ヘキサン中エタノール(30分で50.0%均一濃度)。(1R,4R)-N-シアノ-N-メチル-4-[4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル]シクロヘキサン-1-アミンを得た(14 mg, 5%)。HPLC: 99.5%, RT = 3.382 min. MS: m/z = 440.1 [M+H]+。 1H-NMR (400 MHz, CD3OD) δ 8.37 (br, 1H), 7.93 (d, J = 2.4Hz, 1H), 7.36-7.40 (m, 2H), 7.05-7.16 (m, 5H), 6.69 (s, 1H), 4.99-4.92 (m, 1H), 3.34-3.31 (m, 1H), 2.90 (s, 3H), 2.29-2.21 (m, 4H), 2.13-2.11 (m, 2H), 1.93-1.85 (m, 2H)。
4-(4-フェノキシ-フェノキシ)-5-ピペリジン-4-イル-5H-ピロロ[3,2-d]ピリミジン (110.00 mg; 0.28 mmol; 1.00eq.)、臭化シアン(83.58μl; 1.14 mmol; 4.00 eq.)をDCM(5.00 ml; 78.00 mmol; 274.04eq.)中に含むマイクロ波バイアルにおいて、DIPEA (0.28 ml; 1.71 mmol; 6.00 eq.)を添加した。反応物を室温にて16時間撹拌し、その後、濃縮し、5mLのEtOHで希釈しそしてろ過した。回収したケークを乾燥し、4-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)ピペリジン-1-カルボニトリル ( 80.0 mg, 68.3%)をオフホワイト固形分として与えた。HPLC: 100 %。MS: m/z = 412 [M+H]+。1H-NMR (DMSO-D6) δ 8.34 (s, 1H), 8.08 (d, 1H), 7.30-7.44 (m, 4H), 7.07-7.22 (m, 5H), 6.69 (d, 1H), 4.95 (m, 1H), 3.54 (d, 2H), 3.25 (m, 2H), 2.20 (m, 4H)。
上記の方法A、C、E及びGにおいて使用された条件と類似の条件を用いて、題記の化合物を4-(4-フェノキシ-フェノキシ)-5-ピペリジン-4-イル-5H-ピロロ[3,2-d]ピリミジン、シアノ酢酸、トリエチルアミン及び2,4,6-トリプロピル-[1,3,5,2,4,6]トリオキサトリホスフィナンを用いて製造した。MS: m/z = 454[M+H]+。
3-オキソ-3-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-イル}-プロピオニトリル (0.50 g; 0.57 mmol; 1.00 eq.)の乾燥DCM (6.65 g; 5.00 ml; 10.00 V)中の溶液にブチルアルデヒド(0.06 g; 0.86 mmol; 1.50 eq.)を添加し、次いで、ピペラジン(0.00 g; 0.06 mmol; 0.10 eq.)を室温にて添加した。反応混合物を室温にて8時間撹拌した。反応をTLCによりモニターした。完了後に、反応混合物を水で希釈し、有機相をブラインで洗浄し、そして無水硫酸ナトリウム上で乾燥した。粗製生成物をカラムクロマトグラフィー(60-120 シリカ)を用いて、石油エーテル及び酢酸エチルを溶離剤(50〜60%)として用いて精製し、(E)-2-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-カルボニル}-へキス-2-エンニトリル (70.00 mg; 0.10 mmol; 16.6 %; 淡黄色ガム; 精製製品)を提供した。 MS: m/z = 508[M+H]+。 1H NMR (400 MHz, DMSO-d6): 8.52 (s, 1H), 7.55-7.54 (m, 1H), 7.40-7.36 (m, 2H), 7.27-7.20 (m, 3H), 7.19-7.13 (m, 4H), 6.80 (t, J = 8.00 Hz, 1H), 5.13 (t, J = 4.00 Hz, 1H), 5.90-5.80 (m, 1H), 4.20-4.10 (m, 1H), 3.30-3.10 (m, 1H), 2.90-2.80 (m, 1H), 2.55-2.50 (m, 2H), 2.38-2.31 (m, 2H), 2.11-2.08 (m, 2H), 1.64-1.55 (m, 2H), 1.03-0.92 (m, 3H)。
1-2-N-Boc-(アミノエチル)-ピペラジン (2.00 g; 8.63 mmol; 1.00 eq.)及びトリエチル-アミン (2.65 g; 3.65 ml; 25.90 mmol; 3.00 eq.)の乾燥THF (17.80 g; 20.00 ml; 10.00 V)中の撹拌された溶液に、(E)-4-ブロモ-ブト-2-エン酸(1.74 g; 10.36 mmol; 1.20 eq.)を0℃で窒素雰囲気下に添加した。添加後に、反応混合物を同一温度でさらに2時間撹拌した。反応混合物を18時間かけてゆっくりと室温にした。完了後に、沈殿した固形分をろ過し、固形分をTHF (25 mL)で洗浄し、そしてろ液を高真空下に蒸発させた。DCM及びメタノールを溶離剤(12〜15%)として用いて、粗製生成物をカラム(60-120シリカゲル)に直接的に装填し、(E)-4-[4-(2-tert-ブトキシカルボニルアミノ-エチル)-ピペラジン-1-イル]-ブト-2-エン酸(1.20 g; 3.48 mmol; 40.4 %)を提供した。MS: m/z = 314[M+H]+(TIC)。
4-(4-フェノキシ-フェノキシ)-5-ピペリジン-4-イル-5H-ピロロ[3,2-d]ピリミジン (0.80 g; 1.80 mmol; 1.00 eq.)の乾燥DCM (10.64 g; 8.00 ml; 10.00 V)中の撹拌されている溶液に、(E)-4-[4-(2-tert-ブトキシカルボニルアミノ-エチル)-ピペラジン-1-イル]-ブト-2-エン酸(0.67 g; 1.98 mmol; 1.10 eq.)を添加し、次いで、トリエチル-アミン (0.55 g; 5.40 mmol; 3.00 eq.)を室温にて添加した。反応混合物を0℃に冷却し、窒素雰囲気下にT3P (酢酸エチル中50%) (1.72 g; 1.70 ml; 2.70 mmol; 1.50 eq.) を添加した。反応混合物をゆっくりと室温に温め、そして6時間撹拌した。反応をTLCによりモニターした。完了後に、反応混合物を10%NaHCO3 溶液で希釈した。有機相を分離し、そして水、ブラインで洗浄し、そして無水硫酸ナトリウム上で乾燥し、{2-[4-((E)-4-オキソ-4-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-イル}-ブト-2-エニル)-ピペラジン-1-イル]-エチル}-カルバミン酸tert-ブチルエステルを提供した(1.47 g; 1.47 mmol; 81.4 %; 無色フォーム;粗製生成物)。MS: m/z = 682[M+H]+
1,4-ジオキサン中の4N HCl及び{2-[4-((E)-4-オキソ-4-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-イル}-ブト-2-エニル)-ピペラジン-1-イル]-エチル}-カルバミン酸tert-ブチルエステル(1.00 g; 0.00 mol; 1.00 eq.)の混合物を室温にて2時間撹拌した。反応をTLCによりモニターした。完了後に、反応混合物を高真空下に濃縮した。残留物を水(25 mL)で溶解し、そして水性層を酢酸エチルで洗浄した(25 mL X 3)。水性層をNaHCO3 (固形分)で塩基性化し(約PH=8)、そして酢酸エチルで抽出した(25 mL X 3)。合わせた有機層をブラインで洗浄し、そして高真空下に蒸発させ、(E)-4-[4-(2-アミノ-エチル)-ピペラジン-1-イル]-1-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-イル}-ブト-2-エン-1-オン (0.60 g; 0.77 mmol; 79.9 %)を提供した。 MS: m/z = 582[M+H]+
(E)-4-[4-(2-アミノ-エチル)-ピペラジン-1-イル]-1-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-イル}-ブト-2-エン-1-オン(1.00 g; 1.29 mmol; 1.00 eq.)の乾燥DCM (13.30 g; 10.00 ml; 10.00 V)中の撹拌されている溶液に、3-(2-{2-[2-(2-tert-ブトキシカルボニルアミノ-エトキシ)-エトキシ]-エトキシ}-エトキシ)-プロピオン酸(0.58 g; 1.55 mmol; 1.20 eq.)を添加し、次いで、トリエチルアミン (0.40 g; 0.55 ml; 3.87 mmol; 3.00 eq.)を室温で添加した。反応混合物を0〜5℃に冷却し、そしてT3Pを添加した(酢酸エチル中50%) (1.23 g; 1.22 ml; 1.93 mmol; 1.50 eq.)。反応混合物を室温にて6時間撹拌した。反応をTLCによりモニターした。反応混合物を10% NaHCO3 溶液で撹拌し、そしてDCMで抽出した。有機層を水(25mL)、ブライン(25 mL)で洗浄し、そして無水硫酸ナトリウム上で乾燥した。粗製生成物を、カラムクロマトグラフィー(60-120シリカ)により、クロロホルム及びメタノールを溶離剤(2〜5%)として用いて精製し、[2-(2-{2-[2-(2-{2-[4-((E)-4-オキソ-4-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-イル}-ブト-2-エニル)-ピペラジン-1-イル]-エチルカルバモイル}-エトキシ)- エトキシ]- エトキシ}-エトキシ)-エチル]-カルバミン酸tert-ブチルエステルを提供した(0.43 g; 0.43 mmol; 33.4 %; 無色ガム)。 MS: m/z = 930[M+H]+。 1H NMR (400 MHz, DMSO-d6):8.31 (s, 1H), 8.02 (d, J = 4.00 Hz, 1H), 7.74 (t, J = 4.00 Hz, 1H), 7.39-7.35 (m, 2H), 7.34-7.33 (m, 2H), 7.17-7.10 (m, 1H), 7.10-7.04 (m, 4H), 6.75-6.70 (m, 1H), 6.66-6.55 (m, 3H), 5.04-5.00 (m, 1H), 4.55-4.53 (m, 1H), 4.30-4.20 (m, 1H), 3.58-3.50 (m, 2H), 3.48-3.47 (m, 12H), 3.46-3.37 (m, 2H), 3.35-3.32 (m, 1H), 3.32-3.30 (m, 2H), 3.15-3.12 (m, 4H), 2.55-2.50 (m, 1H), 2.49-2.48 (m, 10H), 2.28-2.20 (m, 2H), 1.98-1.90 (m, 2H), 1.35 (s, 9H)。
[2-(2-{2-[2-(2-{2-[4-((E)-4-オキソ-4-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-イル}-ブト-2-エニル)-ピペラジン-1-イル]-エチルカルバモイル}-エトキシ)- エトキシ]- エトキシ}-エトキシ)-エチル]-カルバミン酸tert-ブチルエステル(0.38 mmol; 1.00 eq.; 350.00 mg)を、ジオキサン中の4N HCl (10.00 ml)及びメタノール(74.06 mmol; 196.60 eq.; 2373.00 mg; 3.00 ml) と混合した。混合物を室温で1時間撹拌した。すべての溶媒を、その後、除去し、粗製生成物を高真空で一晩乾燥し、3-(2-{2-[2-(2-アミノ-エトキシ)- エトキシ]- エトキシ}-エトキシ)-N-{2-[4-((E)-4-オキソ-4-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-イル}-ブト-2-エニル)-ピペラジン-1-イル]-エチル}-プロピオンアミド(314.00 mg; 0.38 mmol)を提供し、それを精製せずに使用した。MS: m/z = 830[M+H]+。 1H NMR (400 MHz, DMSO-d6) δ 8.45 (s, 1H), 8.22 (s, 2H), 8.15 - 8.04 (m, 2H), 7.88 (s, 4H), 7.58 - 7.30 (m, 1H), 7.30 - 6.93 (m, 2H), 6.80 - 6.51 (m, 2H), 5.12 (s, 2H), 4.65 (d, J = 13.8 Hz, 2H), 4.28 (s, 1H), 4.00 - 3.15 (m, 16H), 3.07 - 2.71 (m, 6H), 2.44 - 2.15 (m, 5H), 2.02 (d, J = 13.4 Hz, 1H)。
3-(2-{2-[2-(2-アミノ-エトキシ)- エトキシ]-エトキシ}-エトキシ)-N-{2-[4-((E)-4-オキソ-4-{4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-イル}-ブト-2-エニル)-ピペラジン-1-イル]-エチル}-プロピオンアミド(0.07 mmol; 1.00 eq.; 59.00 mg)を5,5-ジフルオロ-10-(4-イソチオシアナトフェニル)-1,3,7,9-テトラメチル-5H-4l4,5l4-ジピロロ[1,2-c:2',1'-f][1,3,2]ジアザボリニン(0.08 mmol; 1.10 eq.; 29.85 mg)、N-エチルジイソプロピルアミン (0.21 mmol; 3.00 eq.; 27.60 mg; 0.04 ml)及びMeCN (38.29 mmol; 538.03 eq.; 1572.00 mg; 2.00 ml)と混合した。混合物を室温で2時間撹拌した。粗製反応物を逆相分取カラムで20〜80%のCH3CN/H20 (ギ酸0.1%)の勾配を用いて直接精製し、(E)-1-((4-(5,5-ジフルオロ-1,3,7,9-テトラメチル-5H-4l4,5l4-ジピロロ[1,2-c:2',1'-f][1,3,2]ジアザボリニン-10-イル)フェニル)アミノ)-N-(2-(4-(4-オキソ-4-(4-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)ピペリジン-1-イル)ブト-2-エン-1-イル)ピペラジン-1-イル)エチル)-1-チオキソ-5,8,11,14-テトラオキサ-2-アザヘプタデカン-17-アミド(22.10 mg, 0.02 mmol, 23.8%)を黄色固形分として提供した。MS: m/z = 605[M+H/2]+。 1H NMR (400 MHz, DMSO-d6):8.31 (s, 1H), 8.02 (d, J = 4.00 Hz, 1H), 7.74 (t, J = 4.00 Hz, 1H), 7.39-7.35 (m, 4H), 7.34-7.33 (m, 6H), 7.17-7.10 (m, 1H), 7.10-7.04 (m, 4H), 6.75-6.70 (m, 1H), 6.66-6.55 (m, 3H), 5.04-5.00 (m, 1H), 4.55-4.53 (m, 1H), 4.30-4.20 (m, 1H), 3.58-3.50 (m, 2H), 3.48-3.47 (m, 12H), 3.46-3.37 (m, 2H), 3.35-3.32 (m, 1H), 3.32-3.30 (m, 2H), 3.15-3.12 (m, 4H), 2.55-2.50 (m, 1H), 2.49-2.48 (m, 23H), 2.28-2.20 (m, 2H), 1.98-1.90 (m, 2H)。
シアナミド(0.69 mmol; 2.10 eq.; 28.81 mg)をTHF中に溶解し、その後、アイスバスで0℃に冷却した。NaH (60%) (0.82 mmol; 2.50 eq.; 32.63 mg)を、その後、1回で添加し、そして混合物をアイスバスで窒素下に30分間撹拌した。4-[4-(4-フェノキシ-フェノキシ)-ピロロ[3,2-d]ピリミジン-5-イル]-ピペリジン-1-カルボン酸4-ニトロ-フェニルエステル(0.33 mmol; 1.00 eq.; 179.98 mg)をその後、撹拌されている溶液に添加し、そしてアイスバスを取り除いた。混合物を室温にて一晩撹拌した。粗製反応物を、その後、飽和重炭酸塩でクエンチし、そしてEtOACで3回抽出した。飽和NaCl溶液を添加し、そしてEtOACでさらに3回抽出した。有機物を合わせ、そして乾燥まで濃縮し、そして逆相クロマトグラフィーにより10〜100% CH3CN/H2O (0.1% 水酸化アンモニウム)を用いて精製し、N-シアノ-4-(4-(4-フェノキシフェノキシ)-5H-ピロロ[3,2-d]ピリミジン-5-イル)ピペリジン-1-カルボキサミドを提供した。MS: m/z = 455[M+H]+。 1H-NMR (MeOH-d4) δ 8.31 (s, 1H), 8.13 (s, 1H), 7.25 (m, 5H), 7.0 (m, 5H), 6.76 (d, 1H), 6.12 (d, 1H), 5.64 (d, 1H), 5.25 (s, 1H), 4.61 (d, 1H), 4.23 (d, 1H), 3.28 (m, 1H), 2.99 (t, 1H), 2.19 (m, 4H)。
BTK IC50 酵素アッセイ(アッセイA)
以下はBTK酵素に対する化合物の固有効力を測定するために使用される、ミクロ流体のオフチップ移動度シフトキナーゼアッセイを記載する。
Btkは抗-IgM刺激後にB細胞抗体受容体(BCR)のシグナル伝達を媒介するのに重要である。この原理に基づいて、機能細胞系アッセイは新鮮に分離したヒト末梢血単核球(PBMC)中で、下流BCRシグナル伝達イベントである、CD69の抗-IgM-誘導発現を阻害する際の化合物の効力を決定するように確立された。このアッセイにおいて、2.5x 105 個の細胞を含む90μl PBMC懸濁液を、様々な濃度の10μl試験化合物で1時間予備処理し、その後、5μlの420μg/ml affiniPure F(ab')2 断片ヤギ抗ヒトIgM Fc断片/ウェル(Dianova, Cat.No.: 109-006-129)とともに一晩インキュベートした(約16〜18時間)。インキュベーションの後に、細胞を洗浄し、そしてAPC ラベル化マウス抗-ヒトCD69 (BD Biosciences; クローン: FN50)、PerCP-Cy5.5ラベル化マウス抗ヒトCD19 (BD Biosciences; クローン: SJ25C1)及びFITC-ラベル化マウス抗-ヒトCD3 (BD Biosciences; clone: HIT3a)で免疫染色し、そしてCD19 陽性細胞(B細胞)上のCD69発現のフローサイトメトリー解析のために固定化させた。CD19 陽性細胞のCD69発現を試験化合物の濃度に対してプロットし、濃度応答曲線を得た。そしてアッセイにおける試験化合物の効力の測定値としてのIC50 値を計算する。
医薬製剤
(A)注射バイアル:本発明に係る活性成分100g及びリン酸水素二ナトリウム5gの3lの二回蒸留した水中の溶液を、2N塩酸を用いてpH 6.5に調節し、無菌ろ過し、注射バイアル中に移し、無菌状態で凍結乾燥し、そして無菌条件下でシールする。各注射バイアルは5 mgの活性成分を含む。
Claims (21)
- 式Iの化合物又はその医薬上許容される塩、
X1 はN又はCR2であり、
X2 はN又はCR2であり、
各R2は-R、ハロゲン、-ハロアルキル、-OR、-SR、-CN、-NO2、-SO2R、-SOR、-C(O)R、-CO2R、-C(O)N(R)2、-NRC(O)R、-NRC(O)N(R)2、-NRSO2R又は-N(R)2から独立して選ばれ、
各Rは独立して、水素、C1-6 脂肪族、C3-10 アリール、3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する3〜7員複素環、又は、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する5〜6 員単環式ヘテロアリール環であり、その各々は場合により置換されていてよく、又は、
同一原子上の2つのR基はそれらが結合している原子と一緒になって、C3-10 アリール、3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する3〜7員複素環、又は、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する5〜6員単環式ヘテロアリール環を形成し、その各々は場合により置換されていてよく、
LはC1-6 脂肪族、C3-10 アリール、3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する3〜7員複素環、及び、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する5〜6員単環式ヘテロアリール環から選ばれ、その各々は場合により置換されていてよい二価基であり、又は、Lは、C1-6 脂肪族-C3-10アリール、C1-6 脂肪族-3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有するC1-6 脂肪族-3〜7 員複素環、及び、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有するC1-6脂肪族-5〜6 員単環式ヘテロアリール環から選ばれ、その各々は場合により置換されていてよい二価基であり、
Y はO、S、SO2、SO、C(O)、CO2、C(O)N(R)、-NRC(O)、-NRC(O)N(R)、-NRSO2又はN(R)であり、又は、Yは存在せず、
R1 はC1-6 脂肪族、C3-10アリール、3〜8員飽和もしくは部分不飽和炭素環、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する3〜7員複素環、又は、窒素、酸素又は硫黄から独立して選ばれる1〜4個のヘテロ原子を有する5〜6員単環式ヘテロアリール環であり、その各々は場合により置換されていてよく、又は、R1 はCNである)。 - 各R2 は独立して、フェニル又はピラゾリルである、請求項1記載の化合物。
- 各R2は独立して、-OR又は-N(R)2である、請求項1記載の化合物。
- Yは存在しない、請求項1記載の化合物。
- 表1から選ばれる、請求項1記載の化合物。
- 請求項1記載の化合物及び医薬上許容されるアジュバント、担体又はビヒクルを含む、医薬組成物。
- 患者又は生物学的サンプルにおいてBTK又はその変異体の活性を阻害する方法であって、請求項1記載の化合物又はその生理学的に許容される塩を前記患者に投与し又は前記生物学的サンプルと接触させる工程を含む方法。
- BTK-媒介性疾患の治療を必要とする患者においてその治療をするための方法であって、請求項1記載の化合物を前記患者に投与する工程を含む方法。
- BTK-媒介性疾患は炎症性腸疾患、関節炎、全身性エリテマトーデス(SLE又は狼瘡)、ループス腎炎、血管炎、特発性血小板減少性紫斑病(ITP)、関節リウマチ、乾癬性関節炎、変形性関節症、スティル病、若年性関節炎、糖尿病、重症筋無力症、橋本甲状腺炎、オード甲状腺炎、グレーブス病、自己免疫性甲状腺炎、シェーグレン症候群、多発性硬化症、全身性硬化症、ライム神経ボレリア、ギラン・バレー症候群、急性散在性脳脊髄炎、アジソン病、オプソクローヌス・ミオクローヌス症候群、強直性脊椎症、抗リン脂質抗体症候群、再生不良性貧血、自己免疫性肝炎、自己免疫性胃炎、悪性貧血、セリアック病、グッドパスチャー症候群、特発性血小板減少性紫斑病、視神経炎、強皮症、原発性胆汁性肝硬変、ライター症候群、高安動脈炎、側頭動脈炎、温式自己免疫性溶血性貧血、ウェゲナー肉芽腫症、乾癬、全身性脱毛症、ベーチェット病、慢性疲労、自律神経障害、膜性糸球体腎症、子宮内膜症、間質性膀胱炎、尋常性天疱瘡、水疱性類天疱瘡、神経性筋強直、強皮症又は外陰部痛である、請求項18記載の方法。
- BTK-媒介性疾患の予防的又は治療的処置のための医薬の製造のための、請求項1記載の化合物又はその薬理学的に許容される塩の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361860401P | 2013-07-31 | 2013-07-31 | |
US61/860,401 | 2013-07-31 | ||
PCT/US2014/048810 WO2015017502A1 (en) | 2013-07-31 | 2014-07-30 | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016531119A true JP2016531119A (ja) | 2016-10-06 |
JP6612751B2 JP6612751B2 (ja) | 2019-11-27 |
Family
ID=51303133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016531850A Active JP6612751B2 (ja) | 2013-07-31 | 2014-07-30 | Btkの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
Country Status (24)
Country | Link |
---|---|
US (2) | US9738648B2 (ja) |
EP (1) | EP3049417B1 (ja) |
JP (1) | JP6612751B2 (ja) |
KR (1) | KR20160036053A (ja) |
CN (1) | CN105814057B (ja) |
AU (1) | AU2014296261B2 (ja) |
BR (1) | BR112016001600A8 (ja) |
CA (1) | CA2918242C (ja) |
DK (1) | DK3049417T3 (ja) |
ES (1) | ES2706150T3 (ja) |
HR (1) | HRP20190054T1 (ja) |
HU (1) | HUE042111T2 (ja) |
IL (1) | IL243844B (ja) |
LT (1) | LT3049417T (ja) |
MX (1) | MX367085B (ja) |
NZ (1) | NZ715838A (ja) |
PL (1) | PL3049417T3 (ja) |
PT (1) | PT3049417T (ja) |
RS (1) | RS58361B1 (ja) |
RU (1) | RU2712220C2 (ja) |
SG (2) | SG11201600159TA (ja) |
SI (1) | SI3049417T1 (ja) |
WO (1) | WO2015017502A1 (ja) |
ZA (1) | ZA201600564B (ja) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
CA2981530A1 (en) | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
HUE064244T2 (hu) * | 2015-11-17 | 2024-02-28 | Merck Patent Gmbh | Módszerek szklerózis multiplex kezelésére BTK gátló aktivitású pirimidin- és piridin-származékokkal |
CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
AU2017312970B2 (en) * | 2016-08-16 | 2021-08-12 | Merck Patent Gmbh | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
TWI771327B (zh) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
CN106831787B (zh) * | 2017-01-20 | 2018-10-23 | 成都倍特药业有限公司 | 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用 |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
CA3063440A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Covalent inhibitors of kras |
JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
WO2018234775A1 (en) | 2017-06-20 | 2018-12-27 | Mission Therapeutics Limited | SUBSTITUTED CYANOPYRROLIDINES HAVING ACTIVITY AS DUB INHIBITORS |
CN108467387A (zh) * | 2018-06-22 | 2018-08-31 | 苏州市贝克生物科技有限公司 | 阿法替尼异构体杂质的合成方法 |
KR102612513B1 (ko) | 2018-07-31 | 2023-12-12 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
BR112021006488A2 (pt) | 2018-10-05 | 2021-07-06 | Annapurna Bio Inc | compostos e composições para o tratamento de condições associadas com atividade do receptor apj |
EP3873471A4 (en) * | 2018-10-31 | 2022-06-15 | Merck Sharp & Dohme Corp. | N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
EP3982958A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
CR20210580A (es) * | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b |
JP2022536773A (ja) | 2019-06-14 | 2022-08-18 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換ピラゾロピラジン及びglun2b受容体調節因子としてのそれらの使用 |
AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
CN110184115A (zh) * | 2019-07-04 | 2019-08-30 | 李洪 | 环保冷却液及其制备方法 |
GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4132925A1 (en) | 2020-04-08 | 2023-02-15 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
US20230219939A1 (en) | 2020-05-28 | 2023-07-13 | Mission Therapeutics Limited | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction |
CA3185654A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
KR20230022215A (ko) | 2020-06-08 | 2023-02-14 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애, 암 및 섬유증의 치료에 사용하기 위한 USP30 억제제로서 1-(5-(2-시아노피리딘-4-일)옥사졸-2-카보닐)-4-메틸헥사하이드로피롤로[3,4-b]피롤-5(1H)-카보니트릴 |
CN113943294A (zh) * | 2020-07-15 | 2022-01-18 | 成都海博为药业有限公司 | 一种作为btk抑制剂的化合物及其制备方法与用途 |
GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
AR124048A1 (es) * | 2020-11-13 | 2023-02-08 | Biogen Ma Inc | Inhibidores de la btk |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
AR126251A1 (es) | 2021-06-28 | 2023-10-04 | Blueprint Medicines Corp | Inhibidores de cdk2 |
KR102664046B1 (ko) | 2021-11-25 | 2024-05-08 | 광동제약 주식회사 | 식물공장 시스템을 이용한 인삼 및 인삼 클론 대량생산 방법 |
WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
WO2024048809A1 (ko) * | 2022-08-31 | 2024-03-07 | 보로노이 주식회사 | N을 포함하는 헤테로아릴 유도체, 이를 포함하는 약학적 조성물, 및 이의 용도 |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1212012A1 (ru) * | 1984-10-05 | 1996-03-20 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 4,5-дигидропирроло[1,2,3-е,d]птеридина, обладающие противоопухолевой активностью, и способ их получения |
WO2005019219A1 (ja) * | 2003-08-26 | 2005-03-03 | Teijin Pharma Limited | ピロロピリミジノン誘導体 |
US20050080053A1 (en) * | 2003-08-29 | 2005-04-14 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
WO2005118588A1 (ja) * | 2004-06-02 | 2005-12-15 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
JP2008508192A (ja) * | 2004-07-30 | 2008-03-21 | メチルジーン インコーポレイテッド | Vegfレセプターおよびhgfレセプターシグナル伝達の阻害剤 |
WO2008072634A1 (ja) * | 2006-12-12 | 2008-06-19 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
JP2009500295A (ja) * | 2005-07-05 | 2009-01-08 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
JP2009517333A (ja) * | 2005-12-02 | 2009-04-30 | 武田薬品工業株式会社 | 縮合複素環化合物 |
WO2009113560A1 (ja) * | 2008-03-12 | 2009-09-17 | 武田薬品工業株式会社 | 縮合複素環化合物 |
WO2010036910A1 (en) * | 2008-09-26 | 2010-04-01 | Yoshikazu Ohta | Heart protection by administering an amp-activated protein kinase activator |
JP2010512331A (ja) * | 2006-12-06 | 2010-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイド模倣薬、それらの製造方法、医薬組成物、及びこれらの使用 |
JP2010525039A (ja) * | 2007-04-26 | 2010-07-22 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 4−アザインドール誘導体及び殺菌剤としてのその使用 |
WO2012150866A1 (en) * | 2011-05-03 | 2012-11-08 | Industrial Research Limited | Phosphoribosyltransferase inhibitors and uses thereof |
WO2012158785A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
WO2012158795A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2013010380A1 (en) * | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2013010868A1 (en) * | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors |
JP2013507368A (ja) * | 2009-10-08 | 2013-03-04 | メルク・シャープ・アンド・ドーム・コーポレーション | Bace阻害薬としてのイミノチアジアジンジオキシド化合物、組成物およびその使用 |
WO2013041605A1 (en) * | 2011-09-20 | 2013-03-28 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
JP2013518098A (ja) * | 2010-01-29 | 2013-05-20 | ハンミ ファーム. シーオー., エルティーディー. | タンパク質キナーゼ阻害活性を有する二環式ヘテロアリール誘導体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
-
2014
- 2014-07-30 HU HUE14750672A patent/HUE042111T2/hu unknown
- 2014-07-30 RS RS20190061A patent/RS58361B1/sr unknown
- 2014-07-30 CN CN201480054015.4A patent/CN105814057B/zh active Active
- 2014-07-30 NZ NZ715838A patent/NZ715838A/en not_active IP Right Cessation
- 2014-07-30 SG SG11201600159TA patent/SG11201600159TA/en unknown
- 2014-07-30 WO PCT/US2014/048810 patent/WO2015017502A1/en active Application Filing
- 2014-07-30 CA CA2918242A patent/CA2918242C/en active Active
- 2014-07-30 PT PT14750672T patent/PT3049417T/pt unknown
- 2014-07-30 RU RU2016106760A patent/RU2712220C2/ru not_active IP Right Cessation
- 2014-07-30 JP JP2016531850A patent/JP6612751B2/ja active Active
- 2014-07-30 KR KR1020167005026A patent/KR20160036053A/ko not_active Application Discontinuation
- 2014-07-30 PL PL14750672T patent/PL3049417T3/pl unknown
- 2014-07-30 SI SI201431044T patent/SI3049417T1/sl unknown
- 2014-07-30 US US14/904,547 patent/US9738648B2/en active Active
- 2014-07-30 LT LTEP14750672.9T patent/LT3049417T/lt unknown
- 2014-07-30 MX MX2016001146A patent/MX367085B/es active IP Right Grant
- 2014-07-30 SG SG10201900025UA patent/SG10201900025UA/en unknown
- 2014-07-30 AU AU2014296261A patent/AU2014296261B2/en active Active
- 2014-07-30 ES ES14750672T patent/ES2706150T3/es active Active
- 2014-07-30 EP EP14750672.9A patent/EP3049417B1/en active Active
- 2014-07-30 DK DK14750672.9T patent/DK3049417T3/en active
- 2014-07-30 BR BR112016001600A patent/BR112016001600A8/pt not_active IP Right Cessation
-
2016
- 2016-01-26 ZA ZA2016/00564A patent/ZA201600564B/en unknown
- 2016-01-28 IL IL24384416A patent/IL243844B/en active IP Right Grant
-
2017
- 2017-04-27 US US15/499,460 patent/US10005784B2/en active Active
-
2019
- 2019-01-08 HR HRP20190054TT patent/HRP20190054T1/hr unknown
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1212012A1 (ru) * | 1984-10-05 | 1996-03-20 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 4,5-дигидропирроло[1,2,3-е,d]птеридина, обладающие противоопухолевой активностью, и способ их получения |
WO2005019219A1 (ja) * | 2003-08-26 | 2005-03-03 | Teijin Pharma Limited | ピロロピリミジノン誘導体 |
US20050080053A1 (en) * | 2003-08-29 | 2005-04-14 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
WO2005118588A1 (ja) * | 2004-06-02 | 2005-12-15 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
JP2008508192A (ja) * | 2004-07-30 | 2008-03-21 | メチルジーン インコーポレイテッド | Vegfレセプターおよびhgfレセプターシグナル伝達の阻害剤 |
JP2009500295A (ja) * | 2005-07-05 | 2009-01-08 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
JP2009517333A (ja) * | 2005-12-02 | 2009-04-30 | 武田薬品工業株式会社 | 縮合複素環化合物 |
JP2010512331A (ja) * | 2006-12-06 | 2010-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイド模倣薬、それらの製造方法、医薬組成物、及びこれらの使用 |
WO2008072634A1 (ja) * | 2006-12-12 | 2008-06-19 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
JP2010525039A (ja) * | 2007-04-26 | 2010-07-22 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 4−アザインドール誘導体及び殺菌剤としてのその使用 |
WO2009113560A1 (ja) * | 2008-03-12 | 2009-09-17 | 武田薬品工業株式会社 | 縮合複素環化合物 |
WO2010036910A1 (en) * | 2008-09-26 | 2010-04-01 | Yoshikazu Ohta | Heart protection by administering an amp-activated protein kinase activator |
JP2013507368A (ja) * | 2009-10-08 | 2013-03-04 | メルク・シャープ・アンド・ドーム・コーポレーション | Bace阻害薬としてのイミノチアジアジンジオキシド化合物、組成物およびその使用 |
JP2013518098A (ja) * | 2010-01-29 | 2013-05-20 | ハンミ ファーム. シーオー., エルティーディー. | タンパク質キナーゼ阻害活性を有する二環式ヘテロアリール誘導体 |
WO2012150866A1 (en) * | 2011-05-03 | 2012-11-08 | Industrial Research Limited | Phosphoribosyltransferase inhibitors and uses thereof |
WO2012158785A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
WO2012158795A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2013010380A1 (en) * | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2013010868A1 (en) * | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors |
WO2013041605A1 (en) * | 2011-09-20 | 2013-03-28 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
Non-Patent Citations (3)
Title |
---|
ISHIKAWA T: "DESIGN AND SYNTHESIS OF NOVEL HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)/EPIDERMAL 以下備考", JOURNAL OF MEDICINAL CHEMISTRY, vol. VOL:54, NR:23,, JPN5016008823, 2011, pages 8030 - 8050, ISSN: 0003994350 * |
REGISTRY(STN)[ONLINE], vol. 掲載日:2011年11月7日以前, JPN7018001904, pages 2018 - 4, ISSN: 0003994351 * |
ZHENGYING PAN: "DISCOVERY OF SELECTIVE IRREVERSIBLE INHIBITORS FOR BRUTON'S TYROSINE KINASE", CHEMMEDCHEM, vol. VOL:2, NR:1,, JPN5016008824, 15 January 2007 (2007-01-15), DE, pages 58 - 61, ISSN: 0003812977 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6612751B2 (ja) | Btkの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 | |
RU2703301C2 (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
CA2727455C (en) | Heteroaryl compounds and uses thereof | |
JP7328987B6 (ja) | Ii型irak阻害剤としてのヘテロアリール化合物及びその使用 | |
RU2743040C2 (ru) | Производные пиримидина в качестве btk ингибиторов и их применение | |
JP2017536369A (ja) | Irakインヒビターとしてのヘテロアリール化合物及びその使用 | |
EA017865B1 (ru) | Ингибиторы тирозинкиназы брутона | |
JP2019528275A (ja) | 可逆性btk阻害剤としてのオキソ−イミダゾピリジン及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170713 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180612 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181207 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190712 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190722 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191001 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191031 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6612751 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |